Flag of the European Union EU Clinical Trials Register Help

Clinical trials

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

  • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).


    The EU Clinical Trials Register currently displays   44334   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     

    < Back to search results

    Download PDF

    Clinical Trial Results:
    A Phase Ib/II Study of GDC-0068 or GDC-0980 with Abiraterone Acetate versus Abiraterone Acetate in Patients with Castration-Resistant Prostate Cancer Previously Treated with Docetaxel-Based Chemotherapy

    Summary
    EudraCT number
    2011-004126-10
    Trial protocol
    GR   CZ   ES   GB   NL   FR   IT  
    Global end of trial date
    31 Aug 2022

    Results information
    Results version number
    v2(current)
    This version publication date
    02 Sep 2023
    First version publication date
    07 Dec 2016
    Other versions
    v1
    Version creation reason

    Trial information

    Close Top of page
    Trial identification
    Sponsor protocol code
    GO27983
    Additional study identifiers
    ISRCTN number
    -
    US NCT number
    NCT01485861
    WHO universal trial number (UTN)
    -
    Sponsors
    Sponsor organisation name
    F. Hoffmann-La Roche AG
    Sponsor organisation address
    Grenzacherstrasse 124, Basel, Switzerland, CH4070
    Public contact
    F. Hoffmann-La Roche AG, F. Hoffmann-La Roche AG, +41 616878333, global.trial_information@roche.com
    Scientific contact
    F. Hoffmann-La Roche AG, F. Hoffmann-La Roche AG, +41 616878333, global.trial_information@roche.com
    Paediatric regulatory details
    Is trial part of an agreed paediatric investigation plan (PIP)
    No
    Does article 45 of REGULATION (EC) No 1901/2006 apply to this trial?
    No
    Does article 46 of REGULATION (EC) No 1901/2006 apply to this trial?
    No
    Results analysis stage
    Analysis stage
    Final
    Date of interim/final analysis
    31 Aug 2022
    Is this the analysis of the primary completion data?
    No
    Global end of trial reached?
    Yes
    Global end of trial date
    31 Aug 2022
    Was the trial ended prematurely?
    No
    General information about the trial
    Main objective of the trial
    The primary objectives of the Phase Ib portion of the study were as follows: To evaluate the safety and tolerability of ipatasertib (GDC-0068), an Akt inhibitor, administered in combination with abiraterone and of apitolisib (GDC-0980), a phosphatidylinositol 3 kinase [PI3K], and/or mammalian target of rapamycin [mTOR] inhibitor, administered in combination with abiraterone. To identify dose-limiting toxicities, estimate the maximum tolerated dose, and identify a recommended Phase II dose of ipatasertib administered in combination with abiraterone and of apitolisib administered in combination with abiraterone. The primary objective of the Phase II portion of the study was to estimate the efficacy as measured by radiographic progression-free survival of ipatasertib (dosed at either 400 milligrams [mg] or 200 mg daily) + abiraterone and prednisone/prednisolone versus placebo + abiraterone and prednisone/prednisolone.
    Protection of trial subjects
    All study participants were required to read and sign an Informed Consent Form.
    Background therapy
    -
    Evidence for comparator
    -
    Actual start date of recruitment
    11 Jan 2012
    Long term follow-up planned
    No
    Independent data monitoring committee (IDMC) involvement?
    No
    Population of trial subjects
    Number of subjects enrolled per country
    Country: Number of subjects enrolled
    Netherlands: 11
    Country: Number of subjects enrolled
    Spain: 46
    Country: Number of subjects enrolled
    United Kingdom: 24
    Country: Number of subjects enrolled
    Czechia: 22
    Country: Number of subjects enrolled
    France: 34
    Country: Number of subjects enrolled
    Greece: 16
    Country: Number of subjects enrolled
    Italy: 49
    Country: Number of subjects enrolled
    Romania: 42
    Country: Number of subjects enrolled
    United States: 54
    Worldwide total number of subjects
    298
    EEA total number of subjects
    220
    Number of subjects enrolled per age group
    In utero
    0
    Preterm newborn - gestational age < 37 wk
    0
    Newborns (0-27 days)
    0
    Infants and toddlers (28 days-23 months)
    0
    Children (2-11 years)
    0
    Adolescents (12-17 years)
    0
    Adults (18-64 years)
    90
    From 65 to 84 years
    201
    85 years and over
    7

    Subject disposition

    Close Top of page
    Recruitment
    Recruitment details
    The study was conducted at 55 centers in 10 countries.

    Pre-assignment
    Screening details
    The study consisted of 3 stages: Phase Ib determined recommended Phase II doses (RP2D) for ipatasertib and apitolisib in combination with abiraterone and prednisone/prednisolone. Phase II compared ipatasertib (400 mg/200 mg daily) versus placebo each combined with abiraterone and prednisone/prednisolone. The third stage included the safety cohort.

    Period 1
    Period 1 title
    Overall Study (overall period)
    Is this the baseline period?
    Yes
    Allocation method
    Randomised - controlled
    Blinding used
    Double blind
    Roles blinded
    Investigator, Subject
    Blinding implementation details
    The Phase Ib portion of the study was open-label. In Phase II, participants and investigators were blinded with regard to treatment status (i.e., ipatasertib vs. placebo). The Safety cohort was open-label.

    Arms
    Are arms mutually exclusive
    Yes

    Arm title
    Phase Ib: Ipatasertib 400 mg
    Arm description
    Participants received ipatasertib 400 mg orally once daily, abiraterone 1000 mg orally once daily, and prednisone/prednisolone 5 mg twice daily (bid) orally continuously in 28-day treatment cycles until disease progression or intolerable toxicity.
    Arm type
    Experimental

    Investigational medicinal product name
    Ipatasertib
    Investigational medicinal product code
    Other name
    GDC-0068
    Pharmaceutical forms
    Capsule, hard
    Routes of administration
    Oral use
    Dosage and administration details
    Ipatasertib was administered orally once daily beginning on Day 1 of Cycle 1 until disease progression or intolerable toxicity.

    Investigational medicinal product name
    Prednisone/Prednisolone
    Investigational medicinal product code
    Other name
    Pharmaceutical forms
    Tablet
    Routes of administration
    Oral use
    Dosage and administration details
    Prednisone/prednisolone was to be taken per local clinical practice/investigator recommendation.

    Investigational medicinal product name
    Abiraterone acetate
    Investigational medicinal product code
    Other name
    Zytiga®
    Pharmaceutical forms
    Tablet
    Routes of administration
    Oral use
    Dosage and administration details
    Abiraterone was administered once a day, at the same time that ipatasertib was taken.

    Arm title
    Phase Ib: Apitolisib 30 mg
    Arm description
    Participants received apitolisib 30 mg orally once daily, abiraterone 1000 mg orally once daily, and prednisone/prednisolone 5 mg bid orally continuously in 28-day treatment cycles until disease progression or intolerable toxicity.
    Arm type
    Experimental

    Investigational medicinal product name
    Apitolisib
    Investigational medicinal product code
    Other name
    GDC-0980
    Pharmaceutical forms
    Film-coated tablet
    Routes of administration
    Oral use
    Dosage and administration details
    Apitolisib was administered daily beginning on Day 1 of Cycle 1 until disease progression or intolerable toxicity.

    Investigational medicinal product name
    Prednisone/Prednisolone
    Investigational medicinal product code
    Other name
    Pharmaceutical forms
    Tablet
    Routes of administration
    Oral use
    Dosage and administration details
    Prednisone/prednisolone was to be taken per local clinical practice/investigator recommendation.

    Investigational medicinal product name
    Abiraterone acetate
    Investigational medicinal product code
    Other name
    Zytiga®
    Pharmaceutical forms
    Tablet
    Routes of administration
    Oral use
    Dosage and administration details
    Abiraterone was administered once a day, at the same time that ipatasertib was taken.

    Arm title
    Phase II: Ipatasertib 400 mg + Abiraterone
    Arm description
    Participants received ipatasertib 400 mg orally once daily, abiraterone 1000 mg orally once daily, and prednisone/prednisolone 5 mg bid orally continuously in 28-day treatment cycles until disease progression or intolerable toxicity.
    Arm type
    Experimental

    Investigational medicinal product name
    Ipatasertib
    Investigational medicinal product code
    Other name
    GDC-0068
    Pharmaceutical forms
    Capsule, hard
    Routes of administration
    Oral use
    Dosage and administration details
    Ipatasertib was administered orally once daily beginning on Day 1 of Cycle 1 until disease progression or intolerable toxicity.

    Investigational medicinal product name
    Prednisone/Prednisolone
    Investigational medicinal product code
    Other name
    Pharmaceutical forms
    Tablet
    Routes of administration
    Oral use
    Dosage and administration details
    Prednisone/prednisolone was to be taken per local clinical practice/investigator recommendation.

    Investigational medicinal product name
    Abiraterone acetate
    Investigational medicinal product code
    Other name
    Zytiga®
    Pharmaceutical forms
    Tablet
    Routes of administration
    Oral use
    Dosage and administration details
    Abiraterone was administered once a day, at the same time that ipatasertib was taken.

    Arm title
    Phase II: Ipatasertib 200 mg + Abiraterone
    Arm description
    Participants received ipatasertib 200 mg orally once daily, abiraterone 1000 mg once orally daily, and prednisone/prednisolone 5 mg bid orally continuously in 28-day treatment cycles until disease progression or intolerable toxicity.
    Arm type
    Experimental

    Investigational medicinal product name
    Ipatasertib
    Investigational medicinal product code
    Other name
    GDC-0068
    Pharmaceutical forms
    Capsule, hard
    Routes of administration
    Oral use
    Dosage and administration details
    Ipatasertib was administered orally once daily beginning on Day 1 of Cycle 1 until disease progression or intolerable toxicity.

    Investigational medicinal product name
    Prednisone/Prednisolone
    Investigational medicinal product code
    Other name
    Pharmaceutical forms
    Tablet
    Routes of administration
    Oral use
    Dosage and administration details
    Prednisone/prednisolone was to be taken per local clinical practice/investigator recommendation.

    Investigational medicinal product name
    Abiraterone acetate
    Investigational medicinal product code
    Other name
    Zytiga®
    Pharmaceutical forms
    Tablet
    Routes of administration
    Oral use
    Dosage and administration details
    Abiraterone was administered once a day, at the same time that ipatasertib was taken.

    Arm title
    Phase II: Placebo + Abiraterone
    Arm description
    Participants received placebo (matched to ipatasertib 400 mg or 200) orally once daily, abiraterone 1000 mg orally once daily, and prednisone/prednisolone 5 mg bid orally continuously in 28-day treatment cycles until disease progression or intolerable toxicity.
    Arm type
    Placebo

    Investigational medicinal product name
    Placebo
    Investigational medicinal product code
    Other name
    Pharmaceutical forms
    Capsule, hard
    Routes of administration
    Oral use
    Dosage and administration details
    Placebo (for Ipatasertib 400 mg or 200 mg) was administered daily beginning on Day 1 of Cycle 1 until disease progression or intolerable toxicity.

    Investigational medicinal product name
    Prednisone/Prednisolone
    Investigational medicinal product code
    Other name
    Pharmaceutical forms
    Tablet
    Routes of administration
    Oral use
    Dosage and administration details
    Prednisone/prednisolone was to be taken per local clinical practice/investigator recommendation.

    Investigational medicinal product name
    Abiraterone acetate
    Investigational medicinal product code
    Other name
    Zytiga®
    Pharmaceutical forms
    Tablet
    Routes of administration
    Oral use
    Dosage and administration details
    Abiraterone was administered once a day, at the same time that ipatasertib was taken.

    Arm title
    Safety Cohort: Ipatasertib 400 mg + Abiraterone
    Arm description
    Participants received ipatasertib 400 mg orally once daily and/or prednisone/prednisolone 5 mg orally once daily or bid and/or abiraterone 1000 mg orally once daily according to the following schedule: ipatasertib in the morning during Cycle 1, Days 1-7; ipatasertib in the morning plus prednisone/prednisolone once at night during Cycle 1, Day 8; ipatasertib in the morning plus prednisone/prednisolone bid (morning and night) during Cycle 1, Days 9-11; ipatasertib in the morning plus prednisone/prednisolone bid (morning and night) and abiraterone in the morning during Cycle 1, Days 12-18; ipatasertib in the evening plus prednisone/prednisolone bid (morning and night) and abiraterone at the same time as ipatasertib during Cycle 1, Days 19-25; Cycle 2 and beyond ipatasertib once daily in the morning or evening, abiraterone at the same time as ipatasertib, and prednisone/prednisolone bid.
    Arm type
    Experimental

    Investigational medicinal product name
    Ipatasertib
    Investigational medicinal product code
    Other name
    GDC-0068
    Pharmaceutical forms
    Capsule, hard
    Routes of administration
    Oral use
    Dosage and administration details
    Ipatasertib was administered orally once daily beginning on Day 1 of Cycle 1 until disease progression or intolerable toxicity.

    Investigational medicinal product name
    Abiraterone acetate
    Investigational medicinal product code
    Other name
    Zytiga®
    Pharmaceutical forms
    Tablet
    Routes of administration
    Oral use
    Dosage and administration details
    Abiraterone was administered once a day, at the same time that ipatasertib was taken starting at Cycle 1, Day 18 and then continuously until disease progression or intolerable toxicity.

    Investigational medicinal product name
    Prednisone/Prednisolone
    Investigational medicinal product code
    Other name
    Pharmaceutical forms
    Tablet
    Routes of administration
    Oral use
    Dosage and administration details
    Prednisone/prednisolone was to be taken per local clinical practice/investigator recommendation starting on Cycle 1, Day 8.

    Number of subjects in period 1
    Phase Ib: Ipatasertib 400 mg Phase Ib: Apitolisib 30 mg Phase II: Ipatasertib 400 mg + Abiraterone Phase II: Ipatasertib 200 mg + Abiraterone Phase II: Placebo + Abiraterone Safety Cohort: Ipatasertib 400 mg + Abiraterone
    Started
    14
    6
    84
    86
    83
    25
    Completed
    0
    0
    1
    0
    0
    0
    Not completed
    14
    6
    83
    86
    83
    25
         Physician decision
    1
    1
    -
    -
    -
    -
         Consent withdrawn by subject
    4
    1
    6
    3
    4
    6
         Study Ended
    -
    -
    7
    8
    6
    -
         Discontinuation of Survival Follow-up
    -
    -
    -
    -
    -
    2
         Death
    1
    -
    67
    71
    68
    2
         Adverse event
    -
    4
    -
    -
    -
    1
         Unspecified
    3
    -
    -
    1
    -
    5
         Progression of disease
    5
    -
    1
    -
    -
    9
         Lost to follow-up
    -
    -
    2
    3
    5
    -

    Baseline characteristics

    Close Top of page
    Baseline characteristics reporting groups
    Reporting group title
    Phase Ib: Ipatasertib 400 mg
    Reporting group description
    Participants received ipatasertib 400 mg orally once daily, abiraterone 1000 mg orally once daily, and prednisone/prednisolone 5 mg twice daily (bid) orally continuously in 28-day treatment cycles until disease progression or intolerable toxicity.

    Reporting group title
    Phase Ib: Apitolisib 30 mg
    Reporting group description
    Participants received apitolisib 30 mg orally once daily, abiraterone 1000 mg orally once daily, and prednisone/prednisolone 5 mg bid orally continuously in 28-day treatment cycles until disease progression or intolerable toxicity.

    Reporting group title
    Phase II: Ipatasertib 400 mg + Abiraterone
    Reporting group description
    Participants received ipatasertib 400 mg orally once daily, abiraterone 1000 mg orally once daily, and prednisone/prednisolone 5 mg bid orally continuously in 28-day treatment cycles until disease progression or intolerable toxicity.

    Reporting group title
    Phase II: Ipatasertib 200 mg + Abiraterone
    Reporting group description
    Participants received ipatasertib 200 mg orally once daily, abiraterone 1000 mg once orally daily, and prednisone/prednisolone 5 mg bid orally continuously in 28-day treatment cycles until disease progression or intolerable toxicity.

    Reporting group title
    Phase II: Placebo + Abiraterone
    Reporting group description
    Participants received placebo (matched to ipatasertib 400 mg or 200) orally once daily, abiraterone 1000 mg orally once daily, and prednisone/prednisolone 5 mg bid orally continuously in 28-day treatment cycles until disease progression or intolerable toxicity.

    Reporting group title
    Safety Cohort: Ipatasertib 400 mg + Abiraterone
    Reporting group description
    Participants received ipatasertib 400 mg orally once daily and/or prednisone/prednisolone 5 mg orally once daily or bid and/or abiraterone 1000 mg orally once daily according to the following schedule: ipatasertib in the morning during Cycle 1, Days 1-7; ipatasertib in the morning plus prednisone/prednisolone once at night during Cycle 1, Day 8; ipatasertib in the morning plus prednisone/prednisolone bid (morning and night) during Cycle 1, Days 9-11; ipatasertib in the morning plus prednisone/prednisolone bid (morning and night) and abiraterone in the morning during Cycle 1, Days 12-18; ipatasertib in the evening plus prednisone/prednisolone bid (morning and night) and abiraterone at the same time as ipatasertib during Cycle 1, Days 19-25; Cycle 2 and beyond ipatasertib once daily in the morning or evening, abiraterone at the same time as ipatasertib, and prednisone/prednisolone bid.

    Reporting group values
    Phase Ib: Ipatasertib 400 mg Phase Ib: Apitolisib 30 mg Phase II: Ipatasertib 400 mg + Abiraterone Phase II: Ipatasertib 200 mg + Abiraterone Phase II: Placebo + Abiraterone Safety Cohort: Ipatasertib 400 mg + Abiraterone Total
    Number of subjects
    14 6 84 86 83 25 273
    Age categorical
    Units: Subjects
    Age continuous
    Number of participants analysed for this parameter were 14, 6, 84, 86, 83, respectively.
    Units: years
        arithmetic mean (standard deviation)
    68.1 ( 9.1 ) 69.3 ( 9.3 ) 66.9 ( 8.5 ) 68.8 ( 7.2 ) 67.6 ( 7.8 ) 73.7 ( 8.8 ) -
    Gender categorical
    Units: Subjects
        Female
    0 0 0 0 0 0 0
        Male
    14 6 84 86 83 25 298

    End points

    Close Top of page
    End points reporting groups
    Reporting group title
    Phase Ib: Ipatasertib 400 mg
    Reporting group description
    Participants received ipatasertib 400 mg orally once daily, abiraterone 1000 mg orally once daily, and prednisone/prednisolone 5 mg twice daily (bid) orally continuously in 28-day treatment cycles until disease progression or intolerable toxicity.

    Reporting group title
    Phase Ib: Apitolisib 30 mg
    Reporting group description
    Participants received apitolisib 30 mg orally once daily, abiraterone 1000 mg orally once daily, and prednisone/prednisolone 5 mg bid orally continuously in 28-day treatment cycles until disease progression or intolerable toxicity.

    Reporting group title
    Phase II: Ipatasertib 400 mg + Abiraterone
    Reporting group description
    Participants received ipatasertib 400 mg orally once daily, abiraterone 1000 mg orally once daily, and prednisone/prednisolone 5 mg bid orally continuously in 28-day treatment cycles until disease progression or intolerable toxicity.

    Reporting group title
    Phase II: Ipatasertib 200 mg + Abiraterone
    Reporting group description
    Participants received ipatasertib 200 mg orally once daily, abiraterone 1000 mg once orally daily, and prednisone/prednisolone 5 mg bid orally continuously in 28-day treatment cycles until disease progression or intolerable toxicity.

    Reporting group title
    Phase II: Placebo + Abiraterone
    Reporting group description
    Participants received placebo (matched to ipatasertib 400 mg or 200) orally once daily, abiraterone 1000 mg orally once daily, and prednisone/prednisolone 5 mg bid orally continuously in 28-day treatment cycles until disease progression or intolerable toxicity.

    Reporting group title
    Safety Cohort: Ipatasertib 400 mg + Abiraterone
    Reporting group description
    Participants received ipatasertib 400 mg orally once daily and/or prednisone/prednisolone 5 mg orally once daily or bid and/or abiraterone 1000 mg orally once daily according to the following schedule: ipatasertib in the morning during Cycle 1, Days 1-7; ipatasertib in the morning plus prednisone/prednisolone once at night during Cycle 1, Day 8; ipatasertib in the morning plus prednisone/prednisolone bid (morning and night) during Cycle 1, Days 9-11; ipatasertib in the morning plus prednisone/prednisolone bid (morning and night) and abiraterone in the morning during Cycle 1, Days 12-18; ipatasertib in the evening plus prednisone/prednisolone bid (morning and night) and abiraterone at the same time as ipatasertib during Cycle 1, Days 19-25; Cycle 2 and beyond ipatasertib once daily in the morning or evening, abiraterone at the same time as ipatasertib, and prednisone/prednisolone bid.

    Subject analysis set title
    Safety Set Ipatasertib 400 mg + Abiraterone
    Subject analysis set type
    Safety analysis
    Subject analysis set description
    The Safety Set for Ipatasertib 400 mg + Abiraterone included all treated participants.

    Subject analysis set title
    Safety Set Ipatasertib 200 mg + Abiraterone
    Subject analysis set type
    Safety analysis
    Subject analysis set description
    There were 2 participants who had been randomized to the Placebo + Abiraterone arm, but received 200 mg ipatasertib for 5 days, and are thus counted in the Ipatasertib 200 mg + Abiraterone for the safety population.

    Subject analysis set title
    Safety Set Placebo + Abiraterone
    Subject analysis set type
    Safety analysis
    Subject analysis set description
    There were 2 participants who had been randomized to the Placebo + Abiraterone arm, but received 200 mg ipatasertib for 5 days, and are thus counted in the Ipatasertib 200 mg + Abiraterone for the safety population.

    Primary: Phase Ib: Percentage of Participants With Dose-Limiting Toxicity (DLTs)

    Close Top of page
    End point title
    Phase Ib: Percentage of Participants With Dose-Limiting Toxicity (DLTs) [1] [2]
    End point description
    DLT: 1 of the following toxicities, at least possibly related to ipatasertib or apitolisib. 1) Grade ≥ 3 non-hematologic, non-hepatic major organ AE; 2) Grade ≥ 3 febrile neutropenia; 3) Grade ≥ 4 neutropenia (absolute neutrophils less than [<] 500 per microliter) lasting greater than (>) 7 days; 4) Grade ≥3 thrombocytopenia associated with acute hemorrhage; 5) Grade ≥4 thrombocytopenia; 6) Grade ≥4 anemia; 7) 1 episode of fasting Grade ≥4 hyperglycemia or 3 episodes of fasting Grade 3 hyperglycemia on separate days within 7 days, as determined by laboratory blood glucose evaluation; 8) Grade ≥3 elevation lasting for > 48 hours for hepatic transaminase or liver-specific alkaline phosphatase or total bilirubin. Adverse events were graded according to the National Cancer Institute Common Terminology Criteria for Adverse Events v 4.0. Safety population: all participants who had received ipatasertib, apitolisib, placebo, or abiraterone treatment on Day 1 of Cycle 1.
    End point type
    Primary
    End point timeframe
    Days 1 to 28 of Cycle 1 (Cycle length = 28 days)
    Notes
    [1] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.
    Justification: Only descriptive analyses were planned to be reported.
    [2] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.
    Justification: Only Phase Ib arms were planned to be included in the analysis.
    End point values
    Phase Ib: Ipatasertib 400 mg Phase Ib: Apitolisib 30 mg
    Number of subjects analysed
    14
    6
    Units: percentage of participants
        number (not applicable)
    0
    0
    No statistical analyses for this end point

    Primary: Phase Ib: Percentage of Participants with Adverse Events (AEs)

    Close Top of page
    End point title
    Phase Ib: Percentage of Participants with Adverse Events (AEs) [3] [4]
    End point description
    An Adverse Event (AE) was defined as any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. Safety Population was defined as all participants who had received ipatasertib, apitolisib, placebo, or abiraterone treatment on Day 1 of Cycle 1.
    End point type
    Primary
    End point timeframe
    Baseline up until 30 days following the last administration of study treatment or until initiation of another anti-cancer therapy, whichever occurs first (up to approximately 10 months).
    Notes
    [3] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.
    Justification: Only descriptive analyses were planned to be reported.
    [4] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.
    Justification: Only Phase Ib arms were planned to be included in the analysis.
    End point values
    Phase Ib: Ipatasertib 400 mg Phase Ib: Apitolisib 30 mg
    Number of subjects analysed
    14
    6
    Units: percentage of participants
        number (not applicable)
    100.0
    100.0
    No statistical analyses for this end point

    Primary: Phase II: Radiographic Progression Free Survival (rPFS) - ITT Population

    Close Top of page
    End point title
    Phase II: Radiographic Progression Free Survival (rPFS) - ITT Population [5]
    End point description
    rPFS: Time from randomization to the first occurrence of disease progression, as determined by investigator review of tumor assessments via CT scan and bone scans, or death on study from any cause, whichever occurred first. Progression was defined as follows: Soft tissue mass (Response Evaluation Criteria in Solid Tumors [RECIST] 1.1): at least 20% increase in sum of diameters of target lesions compared to smallest sum of diameters on-study and absolute increase of at least 5 mm, progression of existing non-target lesions, or presence of new lesions. Bone: ≥ 2 new bone lesions plus 2 additional at confirmation on a second bone scan ≥ 4 weeks later (< 12 weeks after randomization). ≥ 2 new bone lesions consistent with progression, without need for confirmatory bone scan (≥ 12 weeks after randomization). ITT Population was defined as all randomised participants with the participants allocated to the treatment arm according to the randomisation.
    End point type
    Primary
    End point timeframe
    Screening up to radiographic progression or death, whichever occurred first (assessed at screening, after Cycles 3, 5, 7, 9, every three cycles [12 weeks] thereafter up to end of treatment [up to 3.6 years overall]) (cycle length = 28 days)
    Notes
    [5] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.
    Justification: Only Phase II arms were planned to be included in the analysis.
    End point values
    Phase II: Ipatasertib 400 mg + Abiraterone Phase II: Ipatasertib 200 mg + Abiraterone Phase II: Placebo + Abiraterone
    Number of subjects analysed
    84
    86
    83
    Units: months
        median (confidence interval 90%)
    8.18 (6.67 to 10.87)
    8.31 (6.44 to 10.48)
    6.37 (4.60 to 8.34)
    Statistical analysis title
    Unstratified analysis:Ipatasertib 400 mg v Placebo
    Comparison groups
    Phase II: Ipatasertib 400 mg + Abiraterone v Phase II: Placebo + Abiraterone
    Number of subjects included in analysis
    167
    Analysis specification
    Pre-specified
    Analysis type
    superiority
    P-value
    = 0.1606
    Method
    Logrank
    Parameter type
    Hazard ratio (HR)
    Point estimate
    0.77
    Confidence interval
         level
    90%
         sides
    2-sided
         lower limit
    0.56
         upper limit
    1.04
    Statistical analysis title
    Unstratified analysis:Ipatasertib 200 mg v Placebo
    Comparison groups
    Phase II: Ipatasertib 200 mg + Abiraterone v Phase II: Placebo + Abiraterone
    Number of subjects included in analysis
    169
    Analysis specification
    Pre-specified
    Analysis type
    superiority
    P-value
    = 0.53
    Method
    Logrank
    Parameter type
    Hazard ratio (HR)
    Point estimate
    0.89
    Confidence interval
         level
    90%
         sides
    2-sided
         lower limit
    0.66
         upper limit
    1.2
    Statistical analysis title
    Stratified analysis:Ipatasertib 400 mg v Placebo
    Statistical analysis description
    Strata were: prior enzalutamide (Yes vs. No), progression factor (prostate-specific antigen [PSA] only vs. other), and number of prior chemotherapy regimens for metastatic disease (one vs. more than one).
    Comparison groups
    Phase II: Ipatasertib 400 mg + Abiraterone v Phase II: Placebo + Abiraterone
    Number of subjects included in analysis
    167
    Analysis specification
    Pre-specified
    Analysis type
    superiority
    P-value
    = 0.1689
    Method
    Logrank
    Parameter type
    Hazard ratio (HR)
    Point estimate
    0.75
    Confidence interval
         level
    90%
         sides
    2-sided
         lower limit
    0.54
         upper limit
    1.05
    Statistical analysis title
    Stratified analysis:Ipatasertib 200 mg v Placebo
    Statistical analysis description
    Strata were: prior enzalutamide (Yes vs. No), progression factor (PSA only vs. other), and number of prior chemotherapy regimens for metastatic disease (one vs. more than one).
    Comparison groups
    Phase II: Ipatasertib 200 mg + Abiraterone v Phase II: Placebo + Abiraterone
    Number of subjects included in analysis
    169
    Analysis specification
    Pre-specified
    Analysis type
    superiority
    P-value
    = 0.7484
    Method
    Logrank
    Parameter type
    Hazard ratio (HR)
    Point estimate
    0.94
    Confidence interval
         level
    90%
         sides
    2-sided
         lower limit
    0.69
         upper limit
    1.28

    Primary: Phase Ib: Recommended Phase II Dose (RP2D) of Ipatasertib and Apitolisib

    Close Top of page
    End point title
    Phase Ib: Recommended Phase II Dose (RP2D) of Ipatasertib and Apitolisib [6] [7]
    End point description
    RP2D is a dose of a drug which would be used in Phase II stage of the study. RP2D was to be determined based on maximum tolerated dose (MTD) in Phase Ib stage of the study. The highest dose level (in 3+3 escalation scheme) with an acceptable safety profile and with a minimum of 6 participants at which fewer than one-third of participants experienced a DLT was declared the MTD and RP2D. Safety Population was defined as all participants who had received ipatasertib, apitolisib, placebo, or abiraterone treatment on Day 1 of Cycle 1.
    End point type
    Primary
    End point timeframe
    Days 1 to 28 of Cycle 1 (Cycle length = 28 days)
    Notes
    [6] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.
    Justification: Only descriptive analyses were planned to be reported.
    [7] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.
    Justification: Only Phase Ib arms were planned to be included in the analysis.
    End point values
    Phase Ib: Ipatasertib 400 mg Phase Ib: Apitolisib 30 mg
    Number of subjects analysed
    14
    0 [8]
    Units: milligrams
        number (not applicable)
    400
    Notes
    [8] - Based on safety analysis, further testing of apitolisib arm was discontinued.
    No statistical analyses for this end point

    Primary: Phase II: rPFS in Participants With Institute of Cancer Research (ICR) Phosphatase and Tensin Homolog (PTEN) Loss

    Close Top of page
    End point title
    Phase II: rPFS in Participants With Institute of Cancer Research (ICR) Phosphatase and Tensin Homolog (PTEN) Loss [9]
    End point description
    rPFS: Time from randomization to the first occurrence of disease progression, as determined by investigator review of tumor assessments via CT scan and bone scans, or death on study from any cause, whichever occurred first. Progression was defined as follows: Soft tissue mass (RECIST 1.1): at least 20% increase in sum of diameters of target lesions compared to smallest sum of diameters on-study and absolute increase of at least 5 mm, progression of existing non-target lesions, or presence of new lesions. Bone: ≥ 2 new bone lesions plus 2 additional at confirmation on 2nd bone scan ≥ 4 weeks later (< 12 weeks after randomization). ≥ 2 new bone lesions consistent with progression, without need for confirmatory bone scan (≥ 12 weeks after randomization). PTEN status was assessed by RUO IHC assay that was performed at ICR, UK. Samples with 100% of the tumor with no PTEN staining were classified as “ICR PTEN loss”. Number of participants analyzed=participants with PTEN loss.
    End point type
    Primary
    End point timeframe
    Screening up to radiographic progression or death, whichever occurred first (assessed at screening, after Cycles 3, 5, 7, 9, every three cycles [12 weeks] thereafter up to end of treatment [up to 3.6 years overall]) (cycle length = 28 days)
    Notes
    [9] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.
    Justification: Only Phase II arms were planned to be included in the analysis.
    End point values
    Phase II: Ipatasertib 400 mg + Abiraterone Phase II: Ipatasertib 200 mg + Abiraterone Phase II: Placebo + Abiraterone
    Number of subjects analysed
    25
    25
    21
    Units: months
        median (confidence interval 90%)
    11.53 (6.67 to 13.73)
    11.10 (6.34 to 16.36)
    4.60 (4.40 to 6.37)
    Statistical analysis title
    Unstratified analysis:Ipatasertib 400 mg v Placebo
    Comparison groups
    Phase II: Ipatasertib 400 mg + Abiraterone v Phase II: Placebo + Abiraterone
    Number of subjects included in analysis
    46
    Analysis specification
    Pre-specified
    Analysis type
    superiority
    P-value
    = 0.0064
    Method
    Logrank
    Parameter type
    Hazard ratio (HR)
    Point estimate
    0.39
    Confidence interval
         level
    90%
         sides
    2-sided
         lower limit
    0.22
         upper limit
    0.7
    Statistical analysis title
    Unstratified analysis:Ipatasertib 200 mg v Placebo
    Comparison groups
    Phase II: Placebo + Abiraterone v Phase II: Ipatasertib 200 mg + Abiraterone
    Number of subjects included in analysis
    46
    Analysis specification
    Pre-specified
    Analysis type
    superiority
    P-value
    = 0.0285
    Method
    Logrank
    Parameter type
    Hazard ratio (HR)
    Point estimate
    0.46
    Confidence interval
         level
    90%
         sides
    2-sided
         lower limit
    0.25
         upper limit
    0.83

    Secondary: Phase Ib: Time to Cmax (tmax) of Ipatasertib When Co-Administered With Abiraterone

    Close Top of page
    End point title
    Phase Ib: Time to Cmax (tmax) of Ipatasertib When Co-Administered With Abiraterone [10]
    End point description
    Analysis was performed on Pharmacokinetic Analysis Population which included all participants who had evaluable PK data. Here, "n" signifies the number of participants with PK data available for specified timepoint.
    End point type
    Secondary
    End point timeframe
    Pre-dose (0 hour), 1, 2, 4, 6, 24 hours post dose on Days 1, 15 of Cycle 1 (cycle length = 28 days)
    Notes
    [10] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.
    Justification: Only the arm treated with ipatasertib in Phase Ib was planned to be included in the analysis.
    End point values
    Phase Ib: Ipatasertib 400 mg
    Number of subjects analysed
    14
    Units: hours
    median (full range (min-max))
        Cycle 1, Day 1 (n=14)
    2.00 (0.97 to 4.05)
        Cycle 1, Day 15 (n=12)
    2.02 (1.00 to 6.00)
    No statistical analyses for this end point

    Secondary: Phase Ib: Maximum Plasma Concentration (Cmax) of Ipatasertib When Co-Administered With Abiraterone

    Close Top of page
    End point title
    Phase Ib: Maximum Plasma Concentration (Cmax) of Ipatasertib When Co-Administered With Abiraterone [11]
    End point description
    Analysis was performed on Pharmacokinetic Analysis Population which included all participants who had evaluable PK data. Here, "n" signifies the number of participants with PK data available for specified timepoint.
    End point type
    Secondary
    End point timeframe
    Pre-dose (0 hour), 1, 2, 4, 6, 24 hours post dose on Days 1, 15 of Cycle 1 (cycle length = 28 days)
    Notes
    [11] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.
    Justification: Only the arm treated with ipatasertib in Phase Ib was planned to be included in the analysis.
    End point values
    Phase Ib: Ipatasertib 400 mg
    Number of subjects analysed
    14
    Units: ng/mL
    geometric mean (geometric coefficient of variation)
        Cycle 1, Day 1 (n=14)
    269 ( 41.3 )
        Cycle 1, Day 15 (n=12)
    466 ( 36.2 )
    No statistical analyses for this end point

    Secondary: Phase Ib: Cmax of G-037720 (Metabolite of Ipatasertib)

    Close Top of page
    End point title
    Phase Ib: Cmax of G-037720 (Metabolite of Ipatasertib) [12]
    End point description
    G-037220 is N-dealkylated metabolite of ipatasertib and the main metabolite in circulation. Analysis was performed on Pharmacokinetic Analysis Population (only ipatasertib arm) which included all participants who had evaluable PK data. Here, "n" signifies the number of participants with PK data available for specified timepoint.
    End point type
    Secondary
    End point timeframe
    Pre-dose (0 hour), 1, 2, 4, 6, 24 hours post dose on Days 1, 15 of Cycle 1 (cycle length = 28 days)
    Notes
    [12] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.
    Justification: Only the arm treated with ipatasertib in Phase Ib was planned to be included in the analysis.
    End point values
    Phase Ib: Ipatasertib 400 mg
    Number of subjects analysed
    14
    Units: ng/mL
    geometric mean (geometric coefficient of variation)
        Cycle 1, Day 1 (n=14)
    117 ( 64.4 )
        Cycle 1, Day 15 (n=12)
    326 ( 42.4 )
    No statistical analyses for this end point

    Secondary: Phase Ib: tmax of G-037720 (Metabolite of Ipatasertib)

    Close Top of page
    End point title
    Phase Ib: tmax of G-037720 (Metabolite of Ipatasertib) [13]
    End point description
    G-037220 is N-dealkylated metabolite of ipatasertib and the main metabolite in circulation. Analysis was performed on Pharmacokinetic Analysis Population (only ipatasertib arm) which included all participants who had evaluable PK data. Here, "n" signifies the number of participants with PK data available for specified timepoint.
    End point type
    Secondary
    End point timeframe
    Pre-dose (0 hour), 1, 2, 4, 6, 24 hours post dose on Days 1, 15 of Cycle 1 (cycle length = 28 days)
    Notes
    [13] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.
    Justification: Only the arm treated with ipatasertib in Phase Ib was planned to be included in the analysis.
    End point values
    Phase Ib: Ipatasertib 400 mg
    Number of subjects analysed
    14
    Units: hours
    median (full range (min-max))
        Cycle 1, Day 1 (n=14)
    2.00 (1.00 to 4.05)
        Cycle 1, Day 15 (n=12)
    2.10 (1.00 to 6.00)
    No statistical analyses for this end point

    Secondary: Phase Ib: Accumulation Ratio of Ipatasertib When Co-Administered With Abiraterone

    Close Top of page
    End point title
    Phase Ib: Accumulation Ratio of Ipatasertib When Co-Administered With Abiraterone [14]
    End point description
    Accumulation Ratio was caculated as AUC0-24 (Cycle 1 Day 15) divided by AUC0-24 (Cycle 1 Day 1). Analysis was performed on Pharmacokinetic Analysis Population which included all participants who had evaluable PK data Number of participants analyzed=participants with PK data available on both Day 1 and Day 15 of Cycle 1.
    End point type
    Secondary
    End point timeframe
    Pre-dose (0 hour), 1, 2, 4, 6, 24 hours post dose on Days 1, 15 of Cycle 1 (cycle length = 28 days)
    Notes
    [14] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.
    Justification: Only the arm treated with ipatasertib in Phase Ib was planned to be included in the analysis.
    End point values
    Phase Ib: Ipatasertib 400 mg
    Number of subjects analysed
    12
    Units: ratio
        geometric mean (geometric coefficient of variation)
    1.82 ( 40.9 )
    No statistical analyses for this end point

    Secondary: Phase Ib: Total Body Clearance (CL/F) of Ipatasertib When Co-Administered With Abiraterone

    Close Top of page
    End point title
    Phase Ib: Total Body Clearance (CL/F) of Ipatasertib When Co-Administered With Abiraterone [15]
    End point description
    Clearance of a drug is a measure of the rate at which a drug is metabolized or eliminated by normal biological processes. Clearance obtained after oral dose is influenced by the fraction of the dose absorbed. Drug clearance is a quantitative measure of the rate at which a drug substance is removed from the blood. Analysis was performed on Pharmacokinetic Analysis Population which included all participants who had evaluable PK data. Numer of participants analyzed=participants with PK data available on Day 15 of Cycle 1.
    End point type
    Secondary
    End point timeframe
    Pre-dose (0 hour), 1, 2, 4, 6, 24 hours post dose on Days 15 of Cycle 1 (cycle length = 28 days)
    Notes
    [15] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.
    Justification: Only the arm treated with ipatasertib in Phase Ib was planned to be included in the analysis.
    End point values
    Phase Ib: Ipatasertib 400 mg
    Number of subjects analysed
    12
    Units: milliliter per hour (mL/h)
        geometric mean (geometric coefficient of variation)
    99600 ( 50.7 )
    No statistical analyses for this end point

    Secondary: Phase Ib: Area Under The Concentration-Time Curve From Time 0 to 24 Hours (AUC0-24) of Ipatasertib When Co-Administered With Abiraterone

    Close Top of page
    End point title
    Phase Ib: Area Under The Concentration-Time Curve From Time 0 to 24 Hours (AUC0-24) of Ipatasertib When Co-Administered With Abiraterone [16]
    End point description
    Analysis was performed on Pharmacokinetic Analysis Population which included all participants who had evaluable PK data. Here, "n" signifies the number of participants with PK data available for specified timepoint.
    End point type
    Secondary
    End point timeframe
    Pre-dose (0 hour), 1, 2, 4, 6, 24 hours post dose on Days 1, 15 of Cycle 1 (cycle length = 28 days)
    Notes
    [16] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.
    Justification: Only the arm treated with ipatasertib in Phase Ib was planned to be included in the analysis.
    End point values
    Phase Ib: Ipatasertib 400 mg
    Number of subjects analysed
    14
    Units: ng/mL*hours
    geometric mean (geometric coefficient of variation)
        Cycle 1, Day 1 (n=14)
    1710 ( 54.7 )
        Cycle 1, Day 15 (n=12)
    3290 ( 37.0 )
    No statistical analyses for this end point

    Secondary: Phase Ib: Cmax of Apitolisib When Co-Administered With Abiraterone

    Close Top of page
    End point title
    Phase Ib: Cmax of Apitolisib When Co-Administered With Abiraterone [17]
    End point description
    Analysis was performed on Pharmacokinetic Analysis Population which included all participants who had evaluable PK data. Here, "n" signifies the number of participants with PK data available for specified timepoint.
    End point type
    Secondary
    End point timeframe
    Pre-dose (0 hour), 1, 2, 4, 6, 24 hours post dose on Days 1, 15 of Cycle 1 (cycle length = 28 days)
    Notes
    [17] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.
    Justification: Only the arm treated with apitolisib in Phase Ib was planned to be included in the analysis.
    End point values
    Phase Ib: Apitolisib 30 mg
    Number of subjects analysed
    6
    Units: ng/mL
    geometric mean (geometric coefficient of variation)
        Cycle 1, Day 1 (n=6)
    190 ( 35.2 )
        Cycle 1, Day 15 (n=2)
    193 ( 16.2 )
    No statistical analyses for this end point

    Secondary: Phase Ib: Accumulation Ratio of G-037720 (Metabolite of Ipatasertib)

    Close Top of page
    End point title
    Phase Ib: Accumulation Ratio of G-037720 (Metabolite of Ipatasertib) [18]
    End point description
    G-037220 is N-dealkylated metabolite of ipatasertib and the main metabolite in circulation. Accumulation Ratio was caculated as AUC0-24 (Cycle 1 Day 15) divided by AUC0-24 (Cycle 1 Day 1). Analysis was performed on Pharmacokinetic Analysis Population (only ipatasertib arm) which included all participants who had evaluable PK data. Number of participants analyzed=participants with PK data available on both Day 1 and Day 15 of Cycle 1.
    End point type
    Secondary
    End point timeframe
    Pre-dose (0 hour), 1, 2, 4, 6, 24 hours post dose on Days 1, 15 of Cycle 1 (cycle length = 28 days)
    Notes
    [18] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.
    Justification: Only the arm treated with ipatasertib in Phase Ib was planned to be included in the analysis.
    End point values
    Phase Ib: Ipatasertib 400 mg
    Number of subjects analysed
    12
    Units: ratio
        geometric mean (geometric coefficient of variation)
    2.79 ( 54.4 )
    No statistical analyses for this end point

    Secondary: Phase Ib: AUC0-24 of G-037720 (Metabolite of Ipatasertib)

    Close Top of page
    End point title
    Phase Ib: AUC0-24 of G-037720 (Metabolite of Ipatasertib) [19]
    End point description
    G-037220 is N-dealkylated metabolite of ipatasertib and the main metabolite in circulation. Analysis was performed on Pharmacokinetic Analysis Population (only ipatasertib arm) which included all participants who had evaluable PK data. Here, "n" signifies the number of participants with PK data available for specified timepoint.
    End point type
    Secondary
    End point timeframe
    Pre-dose (0 hour), 1, 2, 4, 6, 24 hours post dose on Days 1, 15 of Cycle 1 (cycle length = 28 days)
    Notes
    [19] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.
    Justification: Only the arm treated with ipatasertib in Phase Ib was planned to be included in the analysis.
    End point values
    Phase Ib: Ipatasertib 400 mg
    Number of subjects analysed
    14
    Units: ng/mL*hour
    geometric mean (geometric coefficient of variation)
        Cycle 1, Day 1 (n=14)
    839 ( 70.3 )
        Cycle 1, Day 15 (n=12)
    2850 ( 71.7 )
    No statistical analyses for this end point

    Secondary: Phase Ib: tmax of Apitolisib When Co-Administered With Abiraterone

    Close Top of page
    End point title
    Phase Ib: tmax of Apitolisib When Co-Administered With Abiraterone [20]
    End point description
    Analysis was performed on Pharmacokinetic Analysis Population which included all participants who had evaluable PK data. Here, "n" signifies the number of participants with PK data available for specified timepoint.
    End point type
    Secondary
    End point timeframe
    Pre-dose (0 hour), 1, 2, 4, 6, 24 hours post dose on Days 1, 15 of Cycle 1 (cycle length = 28 days)
    Notes
    [20] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.
    Justification: Only the arm treated with apitolisib in Phase Ib was planned to be included in the analysis.
    End point values
    Phase Ib: Apitolisib 30 mg
    Number of subjects analysed
    6
    Units: hours
    median (full range (min-max))
        Cycle 1, Day 1 (n=6)
    2.02 (1.00 to 4.10)
        Cycle 1, Day 15 (n=2)
    2.04 (2.00 to 2.08)
    No statistical analyses for this end point

    Secondary: Phase Ib: tmax of Abiraterone When Co- Administered With Ipatasertib or GDC-0980

    Close Top of page
    End point title
    Phase Ib: tmax of Abiraterone When Co- Administered With Ipatasertib or GDC-0980 [21]
    End point description
    Analysis was performed on Pharmacokinetic Analysis Population which included all participants who had evaluable PK data. Here, "n" signifies the number of participants with PK data available for specified timepoint.Cycle 1, Day 1 (n=14,6)
    End point type
    Secondary
    End point timeframe
    Pre-dose (0 hour), 1, 2, 4, 6, 24 hours post dose on Days 1, 15 of Cycle 1 (cycle length = 28 days)
    Notes
    [21] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.
    Justification: Only Phase Ib arms were planned to be included in the analysis.
    End point values
    Phase Ib: Ipatasertib 400 mg Phase Ib: Apitolisib 30 mg
    Number of subjects analysed
    14
    6
    Units: hours
    median (full range (min-max))
        Cycle 1, Day 1 (n=14,6)
    2.05 (2.00 to 6.45)
    2.01 (1.00 to 4.03)
        Cycle 1, Day 15 (n=12,2)
    2.17 (2.00 to 6.00)
    3.04 (2.00 to 4.08)
    No statistical analyses for this end point

    Secondary: Phase Ib: Cmax of Abiraterone When Co- Administered With Ipatasertib or GDC-0980

    Close Top of page
    End point title
    Phase Ib: Cmax of Abiraterone When Co- Administered With Ipatasertib or GDC-0980 [22]
    End point description
    Analysis was performed on Pharmacokinetic Analysis Population which included all participants who had evaluable PK data. Here, "n" signifies the number of participants with PK data available for specified timepoint.
    End point type
    Secondary
    End point timeframe
    Pre-dose (0 hour), 1, 2, 4, 6, 24 hours post dose on Days 1, 15 of Cycle 1 (cycle length = 28 days)
    Notes
    [22] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.
    Justification: Only Phase Ib arms were planned to be included in the analysis.
    End point values
    Phase Ib: Ipatasertib 400 mg Phase Ib: Apitolisib 30 mg
    Number of subjects analysed
    14
    6
    Units: ng/mL
    geometric mean (geometric coefficient of variation)
        Cycle 1, Day 1 (n=14,6)
    151 ( 123.6 )
    88.2 ( 218 )
        Cycle 1, Day 15 (n=12,2)
    140 ( 124.4 )
    52.7 ( 182 )
    No statistical analyses for this end point

    Secondary: Phase Ib: AUC0-24 of Apitolisib When Co-Administered With Abiraterone

    Close Top of page
    End point title
    Phase Ib: AUC0-24 of Apitolisib When Co-Administered With Abiraterone [23]
    End point description
    Analysis was performed on Pharmacokinetic Analysis Population which included all participants who had evaluable PK data. Here, "n" signifies the number of participants with PK data available for specified timepoint.
    End point type
    Secondary
    End point timeframe
    Pre-dose (0 hour), 1, 2, 4, 6, 24 hours post dose on Days 1, 15 of Cycle 1 (cycle length = 28 days)
    Notes
    [23] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.
    Justification: Only the arm treated with apitolisib in Phase Ib was planned to be included in the analysis.
    End point values
    Phase Ib: Apitolisib 30 mg
    Number of subjects analysed
    6
    Units: ng/mL*hours
    geometric mean (geometric coefficient of variation)
        Cycle 1, Day 1 (n=6)
    1600 ( 47.5 )
        Cycle 1, Day 15 (n=2)
    1640 ( 5.65 )
    No statistical analyses for this end point

    Secondary: Phase Ib: AUC0-24 of Abiraterone When Co- Administered With Ipatasertib or GDC-0980

    Close Top of page
    End point title
    Phase Ib: AUC0-24 of Abiraterone When Co- Administered With Ipatasertib or GDC-0980 [24]
    End point description
    Analysis was performed on Pharmacokinetic Analysis Population which included all participants who had evaluable PK data. Here, "n" signifies the number of participants with PK data available for specified timepoint. 99999 = Geometric Coefficient of Variation could not be estimated as only 1 participant was evaluated.
    End point type
    Secondary
    End point timeframe
    Pre-dose (0 hour), 1, 2, 4, 6, 24 hours post dose on Days 1, 15 of Cycle 1 (cycle length = 28 days)
    Notes
    [24] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.
    Justification: Only Phase Ib arms were planned to be included in the analysis.
    End point values
    Phase Ib: Ipatasertib 400 mg Phase Ib: Apitolisib 30 mg
    Number of subjects analysed
    12
    6
    Units: ng/mL*hr
    geometric mean (geometric coefficient of variation)
        Cycle 1, Day 1 (n=12,6)
    749 ( 92.0 )
    475 ( 203.4 )
        Cycle 1, Day 15 (n=6,1)
    961 ( 87.2 )
    220 ( 99999 )
    No statistical analyses for this end point

    Secondary: Phase Ib: Plasma Half-Life of Abiraterone When Co- Administered With Ipatasertib or GDC-0980

    Close Top of page
    End point title
    Phase Ib: Plasma Half-Life of Abiraterone When Co- Administered With Ipatasertib or GDC-0980 [25]
    End point description
    Analysis was performed on Pharmacokinetic Analysis Population which included all participants who had evaluable PK data. Here, "n" signifies the number of participants with PK data available for specified timepoint. 99999 = Geometric Coefficient of Variation could not be estimated as only 1 participant was evaluated.
    End point type
    Secondary
    End point timeframe
    Pre-dose (0 hour), 1, 2, 4, 6, 24 hours post dose on Days 1, 15 of Cycle 1 (cycle length = 28 days)
    Notes
    [25] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.
    Justification: Only Phase Ib arms were planned to be included in the analysis.
    End point values
    Phase Ib: Ipatasertib 400 mg Phase Ib: Apitolisib 30 mg
    Number of subjects analysed
    10
    5
    Units: hours
    geometric mean (geometric coefficient of variation)
        Cycle 1, Day 1 (n=10,5)
    5.25 ( 13.0 )
    7.68 ( 26.2 )
        Cycle 1, Day 15 (n=6,1)
    6.92 ( 23.5 )
    14.70 ( 99999 )
    No statistical analyses for this end point

    Secondary: Phase II: Overall Survival - ITT Population

    Close Top of page
    End point title
    Phase II: Overall Survival - ITT Population [26]
    End point description
    Overall survival was defined as the interval between the date of screening and death due to any cause. Overall survival was estimated using Kaplan Meier method. The ITT Population was defined as all randomised participants with the participants allocated to the treatment arm according to the randomisation.
    End point type
    Secondary
    End point timeframe
    Screening up to death (assessed at screening, after Cycles 3, 5, 7, 9, every three cycles [12 weeks] thereafter up to end of treatment [up to 8.9 years overall]) (cycle length = 28 days)
    Notes
    [26] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.
    Justification: Only Phase II arms were planned to be included in the analysis.
    End point values
    Phase II: Ipatasertib 400 mg + Abiraterone Phase II: Ipatasertib 200 mg + Abiraterone Phase II: Placebo + Abiraterone
    Number of subjects analysed
    84
    86
    83
    Units: months
        median (confidence interval 95%)
    18.27 (16.66 to 24.21)
    17.31 (13.83 to 22.41)
    18.37 (13.80 to 20.96)
    Statistical analysis title
    Stratified analysis:Ipatasertib 400 mg v Placebo
    Statistical analysis description
    Strata were: prior enzalutamide (Yes vs. No), progression factor (PSA only vs. other), and number of prior chemotherapy regimens for metastatic disease (one vs. more than one).
    Comparison groups
    Phase II: Ipatasertib 400 mg + Abiraterone v Phase II: Placebo + Abiraterone
    Number of subjects included in analysis
    167
    Analysis specification
    Pre-specified
    Analysis type
    superiority
    P-value
    = 0.5164
    Method
    Logrank
    Parameter type
    Hazard ratio (HR)
    Point estimate
    0.89
    Confidence interval
         level
    95%
         sides
    2-sided
         lower limit
    0.62
         upper limit
    1.27
    Statistical analysis title
    Unstratified analysis:Ipatasertib 400 mg v Placebo
    Comparison groups
    Phase II: Ipatasertib 400 mg + Abiraterone v Phase II: Placebo + Abiraterone
    Number of subjects included in analysis
    167
    Analysis specification
    Pre-specified
    Analysis type
    superiority
    P-value
    = 0.417
    Method
    Logrank
    Parameter type
    Hazard ratio (HR)
    Point estimate
    0.87
    Confidence interval
         level
    95%
         sides
    2-sided
         lower limit
    0.62
         upper limit
    1.22
    Statistical analysis title
    Unstratified analysis:Ipatasertib 200 mg v Placebo
    Comparison groups
    Phase II: Placebo + Abiraterone v Phase II: Ipatasertib 200 mg + Abiraterone
    Number of subjects included in analysis
    169
    Analysis specification
    Pre-specified
    Analysis type
    superiority
    P-value
    = 0.6712
    Method
    Logrank
    Parameter type
    Hazard ratio (HR)
    Point estimate
    0.93
    Confidence interval
         level
    95%
         sides
    2-sided
         lower limit
    0.67
         upper limit
    1.3
    Statistical analysis title
    Stratified analysis:Ipatasertib 200 mg v Placebo
    Statistical analysis description
    Strata were: prior enzalutamide (Yes vs. No), progression factor (PSA only vs. other), and number of prior chemotherapy regimens for metastatic disease (one vs. more than one).
    Comparison groups
    Phase II: Ipatasertib 200 mg + Abiraterone v Phase II: Placebo + Abiraterone
    Number of subjects included in analysis
    169
    Analysis specification
    Pre-specified
    Analysis type
    superiority
    P-value
    = 0.8955
    Method
    Logrank
    Parameter type
    Hazard ratio (HR)
    Point estimate
    1.02
    Confidence interval
         level
    95%
         sides
    2-sided
         lower limit
    0.72
         upper limit
    1.44

    Secondary: Phase Ib: Accumulation Ratio of Abiraterone When Co- Administered With Ipatasertib or GDC-0980

    Close Top of page
    End point title
    Phase Ib: Accumulation Ratio of Abiraterone When Co- Administered With Ipatasertib or GDC-0980 [27]
    End point description
    Accumulation Ratio was caculated as AUC0-24 (Cycle 1 Day 15) divided by AUC0-24 (Cycle 1 Day 1). Analysis was performed on Pharmacokinetic Analysis Population which included all participants who had evaluable PK data. Number of participants analyzed=participants with PK data available on both Day 1 and Day 15 of Cycle 1. 99999 = Geometric Coefficient of Variation could not be estimated as only 1 participant was evaluated.
    End point type
    Secondary
    End point timeframe
    Pre-dose (0 hour), 1, 2, 4, 6, 24 hours post dose on Days 1, 15 of Cycle 1 (cycle length = 28 days)
    Notes
    [27] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.
    Justification: Only Phase Ib arms were planned to be included in the analysis.
    End point values
    Phase Ib: Ipatasertib 400 mg Phase Ib: Apitolisib 30 mg
    Number of subjects analysed
    12
    1
    Units: ratio
        geometric mean (geometric coefficient of variation)
    0.823 ( 70.7 )
    0.882 ( 99999 )
    No statistical analyses for this end point

    Secondary: Phase II: Overall Survival in Participants With ICR IHC PTEN Loss

    Close Top of page
    End point title
    Phase II: Overall Survival in Participants With ICR IHC PTEN Loss [28]
    End point description
    Overall survival was defined as the interval between the date of randomization and death from any cause. Overall survival was estimated using Kaplan Meier method. PTEN status was assessed by RUO IHC assay that was performed at ICR, UK. Samples with 100% of the tumor with no PTEN staining were classified as “ICR PTEN loss”. Number of participants analyzed=participants with PTEN loss.
    End point type
    Secondary
    End point timeframe
    Screening up to death (assessed at screening, after Cycles 3, 5, 7, 9, every three cycles [12 weeks] thereafter up to end of treatment [up to 8.9 years overall]) (cycle length = 28 days)
    Notes
    [28] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.
    Justification: Only Phase II arms were planned to be included in the analysis.
    End point values
    Phase II: Ipatasertib 400 mg + Abiraterone Phase II: Ipatasertib 200 mg + Abiraterone Phase II: Placebo + Abiraterone
    Number of subjects analysed
    25
    25
    21
    Units: months
        median (confidence interval 95%)
    17.12 (12.32 to 28.02)
    28.45 (13.24 to 33.28)
    17.28 (11.30 to 20.96)
    Statistical analysis title
    Unstratified analysis:Ipatasertib 200 mg v Placebo
    Comparison groups
    Phase II: Ipatasertib 200 mg + Abiraterone v Phase II: Placebo + Abiraterone
    Number of subjects included in analysis
    46
    Analysis specification
    Pre-specified
    Analysis type
    superiority
    P-value
    = 0.0157
    Method
    Logrank
    Parameter type
    Hazard ratio (HR)
    Point estimate
    0.45
    Confidence interval
         level
    95%
         sides
    2-sided
         lower limit
    0.23
         upper limit
    0.87
    Statistical analysis title
    Unstratified analysis:Ipatasertib 400 mg v Placebo
    Comparison groups
    Phase II: Ipatasertib 400 mg + Abiraterone v Phase II: Placebo + Abiraterone
    Number of subjects included in analysis
    46
    Analysis specification
    Pre-specified
    Analysis type
    superiority
    P-value
    = 0.1472
    Method
    Logrank
    Parameter type
    Hazard ratio (HR)
    Point estimate
    0.63
    Confidence interval
         level
    95%
         sides
    2-sided
         lower limit
    0.33
         upper limit
    1.19

    Secondary: Phase II: Percentage of Participants With PSA Progression - ITT Population

    Close Top of page
    End point title
    Phase II: Percentage of Participants With PSA Progression - ITT Population [29]
    End point description
    PSA progression was defined as per Prostate Cancer Working Group 2 criteria. PSA progression was defined as a ≥ 25% increase and an absolute increase of ≥ 2 nanogram per milliliter (ng/mL) from the baseline value, or a ≥ 25% increase and an absolute increase of ≥ 2 ng/mL from the nadir if PSA decreases from baseline after treatment, which was confirmed by a second value obtained ≥ 3 weeks later. The ITT Population was defined as all randomised participants with the participants allocated to the treatment arm according to the randomisation.
    End point type
    Secondary
    End point timeframe
    Screening up to PSA progression (assessed at screening, after Cycles 3, 5, 7, 9, every three cycles [12 weeks] thereafter up to end of treatment [up to 3.6 years overall]) (cycle length = 28 days)
    Notes
    [29] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.
    Justification: Only Phase II arms were planned to be included in the analysis.
    End point values
    Phase II: Ipatasertib 400 mg + Abiraterone Phase II: Ipatasertib 200 mg + Abiraterone Phase II: Placebo + Abiraterone
    Number of subjects analysed
    84
    86
    83
    Units: percentage of participants
        number (not applicable)
    57.1
    69.8
    72.3
    No statistical analyses for this end point

    Secondary: Phase II: Percentage of Participants With PSA Progression in Participants With ICR PTEN Loss

    Close Top of page
    End point title
    Phase II: Percentage of Participants With PSA Progression in Participants With ICR PTEN Loss [30]
    End point description
    PSA progression was defined as per Prostate Cancer Working Group 2 criteria. PSA progression was defined as a ≥ 25% increase and an absolute increase of ≥ 2 ng/mL from the baseline value, or a ≥ 25% increase and an absolute increase of ≥ 2 ng/mL from the nadir if PSA decreases from baseline after treatment, which was confirmed by a second value obtained ≥ 3 weeks later. PTEN status was assessed by RUO IHC assay that was performed at ICR, UK. Samples with 100% of the tumor with no PTEN staining were classified as “ICR PTEN loss”. Number of participants analyzed=participants with PTEN loss.
    End point type
    Secondary
    End point timeframe
    Screening up to PSA progression (assessed at screening, after Cycles 3, 5, 7, 9, every three cycles [12 weeks] thereafter up to end of treatment [up to 3.6 years overall]) (cycle length = 28 days)
    Notes
    [30] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.
    Justification: Only Phase II arms were planned to be included in the analysis.
    End point values
    Phase II: Ipatasertib 400 mg + Abiraterone Phase II: Ipatasertib 200 mg + Abiraterone Phase II: Placebo + Abiraterone
    Number of subjects analysed
    25
    25
    21
    Units: percentage of participants
        number (not applicable)
    72.0
    64.0
    66.7
    No statistical analyses for this end point

    Secondary: Phase II: Time to PSA Progression in Participants With ICR PTEN Loss

    Close Top of page
    End point title
    Phase II: Time to PSA Progression in Participants With ICR PTEN Loss [31]
    End point description
    Time to PSA progression: Time from screening to the first occurrence of PSA progression, as determined by investigator. PSA progression was defined as per Prostate Cancer Working Group 2 criteria. PSA progression was defined as a ≥ 25% increase and an absolute increase of ≥ 2 ng/mL from the baseline value, or a ≥ 25% increase and an absolute increase of ≥ 2 ng/mL from the nadir if PSA decreases from baseline after treatment, which was confirmed by a second value obtained ≥ 3 weeks later. PTEN status was assessed by RUO IHC assay that was performed at ICR, UK. Samples with 100% of the tumor with no PTEN staining were classified as “ICR PTEN loss”. Number of participants analyzed=participants with PTEN loss.
    End point type
    Secondary
    End point timeframe
    Screening up to PSA progression (assessed at screening, after Cycles 3, 5, 7, 9, every three cycles [12 weeks] thereafter up to end of treatment [up to 3.6 years overall]) (cycle length = 28 days)
    Notes
    [31] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.
    Justification: Only Phase II arms were planned to be included in the analysis.
    End point values
    Phase II: Ipatasertib 400 mg + Abiraterone Phase II: Ipatasertib 200 mg + Abiraterone Phase II: Placebo + Abiraterone
    Number of subjects analysed
    25
    25
    21
    Units: months
        median (confidence interval 90%)
    3.71 (2.99 to 8.18)
    2.92 (2.07 to 7.39)
    2.79 (1.02 to 4.67)
    Statistical analysis title
    Unstratified analysis:Ipatasertib 200 mg v Placebo
    Comparison groups
    Phase II: Ipatasertib 200 mg + Abiraterone v Phase II: Placebo + Abiraterone
    Number of subjects included in analysis
    46
    Analysis specification
    Pre-specified
    Analysis type
    superiority
    P-value
    = 0.2716
    Method
    Logrank
    Parameter type
    Hazard ratio (HR)
    Point estimate
    0.65
    Confidence interval
         level
    90%
         sides
    2-sided
         lower limit
    0.35
         upper limit
    1.22
    Statistical analysis title
    Unstratified analysis:Ipatasertib 400 mg v Placebo
    Comparison groups
    Phase II: Ipatasertib 400 mg + Abiraterone v Phase II: Placebo + Abiraterone
    Number of subjects included in analysis
    46
    Analysis specification
    Pre-specified
    Analysis type
    superiority
    P-value
    = 0.2906
    Method
    Logrank
    Parameter type
    Hazard ratio (HR)
    Point estimate
    0.68
    Confidence interval
         level
    90%
         sides
    2-sided
         lower limit
    0.37
         upper limit
    1.25

    Secondary: Phase II: Time to PSA Progression - ITT Population

    Close Top of page
    End point title
    Phase II: Time to PSA Progression - ITT Population [32]
    End point description
    Time to PSA progression: Time from screening to the first occurrence of PSA progression, as determined by investigator. PSA progression was defined as per Prostate Cancer Working Group 2 criteria. PSA progression is defined as a ≥ 25% increase and an absolute increase of ≥ 2 ng/mL from the baseline value, or a ≥ 25% increase and an absolute increase of ≥ 2 ng/mL from the nadir if PSA decreases from baseline after treatment, which was confirmed by a second value obtained ≥ 3 weeks later. The ITT Population was defined as all randomised participants with the participants allocated to the treatment arm according to the randomisation.
    End point type
    Secondary
    End point timeframe
    Screening up to PSA progression (assessed at screening, after Cycles 3, 5, 7, 9, every three cycles [12 weeks] thereafter up to end of treatment [up to 3.6 years overall]) (cycle length = 28 days)
    Notes
    [32] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.
    Justification: Only Phase II arms were planned to be included in the analysis.
    End point values
    Phase II: Ipatasertib 400 mg + Abiraterone Phase II: Ipatasertib 200 mg + Abiraterone Phase II: Placebo + Abiraterone
    Number of subjects analysed
    84
    86
    83
    Units: months
        median (confidence interval 90%)
    5.55 (4.17 to 7.39)
    3.78 (2.79 to 5.49)
    3.71 (2.79 to 4.67)
    Statistical analysis title
    Unstratified analysis:Ipatasertib 400 mg v Placebo
    Comparison groups
    Phase II: Ipatasertib 400 mg + Abiraterone v Phase II: Placebo + Abiraterone
    Number of subjects included in analysis
    167
    Analysis specification
    Pre-specified
    Analysis type
    superiority
    P-value
    = 0.0665
    Method
    Logrank
    Parameter type
    Hazard ratio (HR)
    Point estimate
    0.7
    Confidence interval
         level
    90%
         sides
    2-sided
         lower limit
    0.51
         upper limit
    0.97
    Statistical analysis title
    Stratified analysis:Ipatasertib 200 mg v Placebo
    Statistical analysis description
    Strata were: prior enzalutamide (Yes vs. No), progression factor (PSA only vs. other), and number of prior chemotherapy regimens for metastatic disease (one vs. more than one).
    Comparison groups
    Phase II: Ipatasertib 200 mg + Abiraterone v Phase II: Placebo + Abiraterone
    Number of subjects included in analysis
    169
    Analysis specification
    Pre-specified
    Analysis type
    superiority
    P-value
    = 0.789
    Method
    Logrank
    Parameter type
    Hazard ratio (HR)
    Point estimate
    0.95
    Confidence interval
         level
    90%
         sides
    2-sided
         lower limit
    0.7
         upper limit
    1.31
    Statistical analysis title
    Stratified analysis:Ipatasertib 400 mg v Placebo
    Statistical analysis description
    Strata were: prior Enzalutamide (Yes vs. No), progression factor (PSA only vs. other), and number of prior chemotherapy regimens for metastatic disease (one vs. more than one).
    Comparison groups
    Phase II: Ipatasertib 400 mg + Abiraterone v Phase II: Placebo + Abiraterone
    Number of subjects included in analysis
    167
    Analysis specification
    Pre-specified
    Analysis type
    superiority
    P-value
    = 0.071
    Method
    Logrank
    Parameter type
    Hazard ratio (HR)
    Point estimate
    0.7
    Confidence interval
         level
    90%
         sides
    2-sided
         lower limit
    0.5
         upper limit
    0.97
    Statistical analysis title
    Unstratified analysis:Ipatasertib 200 mg v Placebo
    Comparison groups
    Phase II: Placebo + Abiraterone v Phase II: Ipatasertib 200 mg + Abiraterone
    Number of subjects included in analysis
    169
    Analysis specification
    Pre-specified
    Analysis type
    superiority
    P-value
    = 0.9319
    Method
    Logrank
    Parameter type
    Hazard ratio (HR)
    Point estimate
    0.99
    Confidence interval
         level
    90%
         sides
    2-sided
         lower limit
    0.73
         upper limit
    1.33

    Secondary: Phase II: Percentage of Participants With PSA Response - ITT Population

    Close Top of page
    End point title
    Phase II: Percentage of Participants With PSA Response - ITT Population [33]
    End point description
    PSA response was defined as a > 50% decrease in PSA from baseline, which was to be confirmed after ≥ 4 weeks by a confirmatory PSA measurement. The ITT Population was defined as all randomised participants with the participants allocated to the treatment arm according to the randomisation.
    End point type
    Secondary
    End point timeframe
    Baseline up to 30 days after last dose (assessed at baseline, Day 1 of every cycle [starting from Cycle 2] till 30 days after last dose [up to overall 3.6 years]) (cycle length = 28 days)
    Notes
    [33] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.
    Justification: Only Phase II arms were planned to be included in the analysis.
    End point values
    Phase II: Ipatasertib 400 mg + Abiraterone Phase II: Ipatasertib 200 mg + Abiraterone Phase II: Placebo + Abiraterone
    Number of subjects analysed
    84
    86
    83
    Units: percentage of participants
        number (confidence interval 90%)
    36.9 (28.11 to 46.40)
    33.7 (25.29 to 42.93)
    34.9 (26.25 to 43.75)
    Statistical analysis title
    Ipatasertib 200 mg v Placebo
    Comparison groups
    Phase II: Ipatasertib 200 mg + Abiraterone v Phase II: Placebo + Abiraterone
    Number of subjects included in analysis
    169
    Analysis specification
    Pre-specified
    Analysis type
    superiority
    P-value
    = 0.8675
    Method
    Chi-squared
    Parameter type
    Difference in response rates
    Point estimate
    -1.22
    Confidence interval
         level
    90%
         sides
    2-sided
         lower limit
    -13.24
         upper limit
    10.8
    Statistical analysis title
    Ipatasertib 400 mg v Placebo
    Comparison groups
    Phase II: Ipatasertib 400 mg + Abiraterone v Phase II: Placebo + Abiraterone
    Number of subjects included in analysis
    167
    Analysis specification
    Pre-specified
    Analysis type
    superiority
    P-value
    = 0.7913
    Method
    Chi-squared
    Parameter type
    Difference in response rates
    Point estimate
    1.97
    Confidence interval
         level
    90%
         sides
    2-sided
         lower limit
    -10.25
         upper limit
    14.18

    Secondary: Phase II: Percentage of Participants With PSA Response in Participants With ICR PTEN Loss

    Close Top of page
    End point title
    Phase II: Percentage of Participants With PSA Response in Participants With ICR PTEN Loss [34]
    End point description
    PSA response was defined as a > 50% decrease in PSA from baseline, which was to be confirmed after ≥ 4 weeks by a confirmatory PSA measurement. PTEN status was assessed by RUO IHC assay that was performed at ICR, UK. Samples with 100% of the tumor with no PTEN staining were classified as “ICR PTEN loss”. Number of participants analyzed=participants with PTEN loss.
    End point type
    Secondary
    End point timeframe
    Baseline up to 30 days after last dose (assessed at baseline, Day 1 of every cycle [starting from Cycle 2] till 30 days after last dose [up to overall 3.6 years]) (cycle length = 28 days)
    Notes
    [34] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.
    Justification: Only Phase II arms were planned to be included in the analysis.
    End point values
    Phase II: Ipatasertib 400 mg + Abiraterone Phase II: Ipatasertib 200 mg + Abiraterone Phase II: Placebo + Abiraterone
    Number of subjects analysed
    25
    25
    21
    Units: percentage of participants
        number (confidence interval 90%)
    40.0 (24.57 to 58.32)
    44.0 (26.99 to 61.06)
    28.6 (13.24 to 46.41)
    Statistical analysis title
    Ipatasertib 400 mg v Placebo
    Comparison groups
    Phase II: Ipatasertib 400 mg + Abiraterone v Phase II: Placebo + Abiraterone
    Number of subjects included in analysis
    46
    Analysis specification
    Pre-specified
    Analysis type
    superiority
    P-value
    = 0.4176
    Method
    Chi-squared
    Parameter type
    Difference in response rates
    Point estimate
    11.43
    Confidence interval
         level
    90%
         sides
    2-sided
         lower limit
    -11.43
         upper limit
    58.32
    Statistical analysis title
    Ipatasertib 200 mg v Placebo
    Comparison groups
    Phase II: Ipatasertib 200 mg + Abiraterone v Phase II: Placebo + Abiraterone
    Number of subjects included in analysis
    46
    Analysis specification
    Pre-specified
    Analysis type
    superiority
    P-value
    = 0.2802
    Method
    Chi-squared
    Parameter type
    Difference in response rates
    Point estimate
    15.43
    Confidence interval
         level
    90%
         sides
    2-sided
         lower limit
    -7.58
         upper limit
    38.44

    Secondary: Phase II: Percentage of Participants With Objective Response in Participants With ICR PTEN Loss

    Close Top of page
    End point title
    Phase II: Percentage of Participants With Objective Response in Participants With ICR PTEN Loss [35]
    End point description
    Objective response was defined as having a CR or PR according to a RECIST 1.1. CR was defined as disappearance of all target and non-target lesions and no new lesions, all pathological lymph nodes must have decreased to <10 mm in short axis. PR was defined as at least a 30% decrease in the sum of diameters of target lesions (taking as reference the baseline sum diameters), no progression in non-target lesions, and no new lesions. PTEN status was assessed by RUO IHC assay that was performed at ICR, UK. Samples with 100% of the tumor with no PTEN staining were classified as “ICR PTEN loss”. Number of participants analyzed=participants with PTEN loss and evaluable for this endpoint.
    End point type
    Secondary
    End point timeframe
    Screening up to radiographic progression or death, whichever occurred first (assessed at screening, after Cycles 3, 5, 7, 9, every three cycles [12 weeks] thereafter up to end of treatment [up to 3.6 years overall]) (cycle length = 28 days)
    Notes
    [35] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.
    Justification: Only Phase II arms were planned to be included in the analysis.
    End point values
    Phase II: Ipatasertib 400 mg + Abiraterone Phase II: Ipatasertib 200 mg + Abiraterone Phase II: Placebo + Abiraterone
    Number of subjects analysed
    9
    15
    7
    Units: percentage of participants
        number (confidence interval 90%)
    11.1 (1.16 to 39.09)
    26.7 (12.18 to 50.00)
    14.3 (1.49 to 50.00)
    Statistical analysis title
    Ipatasertib 400 mg v Placebo
    Comparison groups
    Phase II: Ipatasertib 400 mg + Abiraterone v Phase II: Placebo + Abiraterone
    Number of subjects included in analysis
    16
    Analysis specification
    Pre-specified
    Analysis type
    superiority
    P-value
    = 0.8489
    Method
    Chi-squared
    Parameter type
    Difference in response rates
    Point estimate
    -3.17
    Confidence interval
         level
    90%
         sides
    2-sided
         lower limit
    -30.93
         upper limit
    24.58
    Statistical analysis title
    Ipatasertib 200 mg v Placebo
    Comparison groups
    Phase II: Ipatasertib 200 mg + Abiraterone v Phase II: Placebo + Abiraterone
    Number of subjects included in analysis
    22
    Analysis specification
    Pre-specified
    Analysis type
    superiority
    P-value
    = 0.5186
    Method
    Chi-squared
    Parameter type
    Difference in response rates
    Point estimate
    12.38
    Confidence interval
         level
    90%
         sides
    2-sided
         lower limit
    -16.36
         upper limit
    41.12

    Secondary: Phase II: Percentage of Participants With Objective Response - ITT Population

    Close Top of page
    End point title
    Phase II: Percentage of Participants With Objective Response - ITT Population [36]
    End point description
    Objective response was defined as having a confirm response (CR) or partial response (PR) according to a RECIST 1.1. CR was defined as disappearance of all target and non-target lesions and no new lesions, all pathological lymph nodes must have decreased to <10 mm in short axis. PR was defined as at least a 30% decrease in the sum of diameters of target lesions (taking as reference the baseline sum diameters), no progression in non-target lesions, and no new lesions. The ITT Population was defined as all randomised participants with the participants allocated to the treatment arm according to the randomisation. Number of participants analysed=participants who were evaluable for this endpoint.
    End point type
    Secondary
    End point timeframe
    Screening up to radiographic progression or death, whichever occurred first (assessed at screening, after Cycles 3, 5, 7, 9, every three cycles [12 weeks] thereafter up to end of treatment [up to 3.6 years overall]) (cycle length = 28 days)
    Notes
    [36] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.
    Justification: Only Phase II arms were planned to be included in the analysis.
    End point values
    Phase II: Ipatasertib 400 mg + Abiraterone Phase II: Ipatasertib 200 mg + Abiraterone Phase II: Placebo + Abiraterone
    Number of subjects analysed
    37
    39
    35
    Units: percentage of participants
        number (confidence interval 90%)
    32.4 (20.56 to 46.41)
    23.1 (13.69 to 35.63)
    22.9 (11.91 to 36.46)
    Statistical analysis title
    Ipatasertib 200 mg v Placebo
    Comparison groups
    Phase II: Ipatasertib 200 mg + Abiraterone v Phase II: Placebo + Abiraterone
    Number of subjects included in analysis
    74
    Analysis specification
    Pre-specified
    Analysis type
    superiority
    P-value
    = 0.9821
    Method
    Chi-squared
    Parameter type
    Difference in response rates
    Point estimate
    0.22
    Confidence interval
         level
    90%
         sides
    2-sided
         lower limit
    -15.89
         upper limit
    16.33
    Statistical analysis title
    Ipatasertib 400 mg v Placebo
    Comparison groups
    Phase II: Ipatasertib 400 mg + Abiraterone v Phase II: Placebo + Abiraterone
    Number of subjects included in analysis
    72
    Analysis specification
    Pre-specified
    Analysis type
    superiority
    P-value
    = 0.3646
    Method
    Chi-squared
    Parameter type
    Difference in response rates
    Point estimate
    9.58
    Confidence interval
         level
    90%
         sides
    2-sided
         lower limit
    -7.65
         upper limit
    26.8

    Secondary: Phase II: Duration of Tumor Response - ITT Population

    Close Top of page
    End point title
    Phase II: Duration of Tumor Response - ITT Population [37]
    End point description
    Duration of tumor response: time period from 1st documentation of objective response (CR/PR) (whichever status was recorded first) to date of 1st occurrence of investigator documented disease progression or death. CR: disappearance of all target and non-target lesions and no new lesions, all pathological lymph nodes must have decreased to <10 mm in short axis. PR: at least 30% decrease in sum of diameters of target lesions (taking as reference baseline sum diameters), no progression in non-target lesions, and no new lesions. Progression: increase by at least 20% in sum of longest diameters of each target lesion, taking as reference smallest sum of longest diameters or appearance of one or more new lesions. Duration of tumor response was estimated using Kaplan Meier method. Number of participants analysed=participants from ITT population who had achieved an objective response. Here, 99999 reflects that data was not evaluable due to insufficient number of events.
    End point type
    Secondary
    End point timeframe
    Screening up to radiographic progression or death, whichever occurred first (assessed at screening, after Cycles 3, 5, 7, 9, every three cycles [12 weeks] thereafter up to end of treatment [up to 3.6 years overall]) (cycle length = 28 days)
    Notes
    [37] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.
    Justification: Only Phase II arms were planned to be included in the analysis.
    End point values
    Phase II: Ipatasertib 400 mg + Abiraterone Phase II: Ipatasertib 200 mg + Abiraterone Phase II: Placebo + Abiraterone
    Number of subjects analysed
    12
    9
    8
    Units: months
        median (confidence interval 90%)
    8.77 (3.75 to 99999)
    99999 (6.47 to 99999)
    99999 (2.76 to 99999)
    Statistical analysis title
    Unstratified analysis:Ipatasertib 400 mg v Placebo
    Comparison groups
    Phase II: Placebo + Abiraterone v Phase II: Ipatasertib 400 mg + Abiraterone
    Number of subjects included in analysis
    20
    Analysis specification
    Pre-specified
    Analysis type
    superiority
    P-value
    = 0.678
    Method
    Logrank
    Parameter type
    Hazard ratio (HR)
    Point estimate
    1.31
    Confidence interval
         level
    90%
         sides
    2-sided
         lower limit
    0.45
         upper limit
    3.8
    Statistical analysis title
    Stratified analysis:Ipatasertib 200 mg v Placebo
    Statistical analysis description
    Strata were: prior enzalutamide (Yes vs. No), progression factor (PSA only vs. other), and number of prior chemotherapy regimens for metastatic disease (one vs. more than one).
    Comparison groups
    Phase II: Ipatasertib 200 mg + Abiraterone v Phase II: Placebo + Abiraterone
    Number of subjects included in analysis
    17
    Analysis specification
    Pre-specified
    Analysis type
    superiority
    P-value
    = 0.4227
    Method
    Logrank
    Parameter type
    Hazard ratio (HR)
    Point estimate
    2.46
    Confidence interval
         level
    90%
         sides
    2-sided
         lower limit
    0.36
         upper limit
    16.59
    Statistical analysis title
    Stratified analysis:Ipatasertib 400 mg v Placebo
    Statistical analysis description
    Strata were: prior enzalutamide (Yes vs. No), progression factor (PSA only vs. other), and number of prior chemotherapy regimens for metastatic disease (one vs. more than one).
    Comparison groups
    Phase II: Ipatasertib 400 mg + Abiraterone v Phase II: Placebo + Abiraterone
    Number of subjects included in analysis
    20
    Analysis specification
    Pre-specified
    Analysis type
    superiority
    P-value
    = 0.7733
    Method
    Logrank
    Parameter type
    Hazard ratio (HR)
    Point estimate
    0.77
    Confidence interval
         level
    90%
         sides
    2-sided
         lower limit
    0.17
         upper limit
    3.5
    Statistical analysis title
    Unstratified analysis:Ipatasertib 200 mg v Placebo
    Comparison groups
    Phase II: Ipatasertib 200 mg + Abiraterone v Phase II: Placebo + Abiraterone
    Number of subjects included in analysis
    17
    Analysis specification
    Pre-specified
    Analysis type
    superiority
    P-value
    = 0.8372
    Method
    Logrank
    Parameter type
    Hazard ratio (HR)
    Point estimate
    0.85
    Confidence interval
         level
    90%
         sides
    2-sided
         lower limit
    0.24
         upper limit
    3.02

    Secondary: Phase II: Percentage of Participants With Circulating Tumor Cells (CTC) Reduction Response - ITT Population

    Close Top of page
    End point title
    Phase II: Percentage of Participants With Circulating Tumor Cells (CTC) Reduction Response - ITT Population [38]
    End point description
    CTC reduction response was defined as participants with a reduction in CTCs of ≥ 30% compared to baseline. The ITT Population was defined as all randomised participants with the participants allocated to the treatment arm according to the randomisation. Number of participants analysed=participants with CTC > 0 cells/7.5 milliliters (mL) at baseline.
    End point type
    Secondary
    End point timeframe
    Baseline, on Day 1 of Cycle 2, on Day 1 of Cycle 3, and at the treatment completion visit (up to overall 3.6 years) (cycle length=28 days)
    Notes
    [38] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.
    Justification: Only Phase II arms were planned to be included in the analysis.
    End point values
    Phase II: Ipatasertib 400 mg + Abiraterone Phase II: Ipatasertib 200 mg + Abiraterone Phase II: Placebo + Abiraterone
    Number of subjects analysed
    58
    62
    63
    Units: percentage of participants
        number (confidence interval 90%)
    67.2 (56.44 to 77.37)
    71.0 (61.07 to 80.32)
    63.5 (52.41 to 73.60)
    Statistical analysis title
    Ipatasertib 400 mg v Placebo
    Comparison groups
    Phase II: Ipatasertib 400 mg + Abiraterone v Phase II: Placebo + Abiraterone
    Number of subjects included in analysis
    121
    Analysis specification
    Pre-specified
    Analysis type
    superiority
    P-value
    = 0.6652
    Method
    Chi-squared
    Parameter type
    Difference in response rates
    Point estimate
    3.75
    Confidence interval
         level
    90%
         sides
    2-sided
         lower limit
    -10.47
         upper limit
    17.97
    Statistical analysis title
    Ipatasertib 200 mg v Placebo
    Comparison groups
    Phase II: Ipatasertib 200 mg + Abiraterone v Phase II: Placebo + Abiraterone
    Number of subjects included in analysis
    125
    Analysis specification
    Pre-specified
    Analysis type
    superiority
    P-value
    = 0.3734
    Method
    Chi-squared
    Parameter type
    Difference in response rates
    Point estimate
    7.48
    Confidence interval
         level
    90%
         sides
    2-sided
         lower limit
    -6.29
         upper limit
    21.24

    Secondary: Phase II: Duration of Tumor Response in Participants with ICR PTEN Loss

    Close Top of page
    End point title
    Phase II: Duration of Tumor Response in Participants with ICR PTEN Loss [39]
    End point description
    Time from 1st documentation of objective response (CR/PR) to 1st occurrence of investigator documented disease progression or death. CR: disappearance of all target and non-target lesions and no new lesions, all pathological lymph nodes must have decreased to <10 mm in short axis. PR: at least 30% decrease in sum of diameters of target lesions, no progression in non-target lesions, and no new lesions. Progression: increase by at least 20% in sum of longest diameters of each target lesion, taking as reference smallest sum of longest diameters or appearance of one or more new lesions. Estimated using Kaplan Meier method. PTEN status was assessed by RUO IHC assay. Samples with 100% of the tumor with no PTEN staining were classified as “ICR PTEN loss”. Number of participants analysed = participants from PTEN loss population who had achieved an objective response. 0.0000/9999/99999 = not estimable due to low number of events
    End point type
    Secondary
    End point timeframe
    Screening up to radiographic progression or death, whichever occurred first (assessed at screening, after Cycles 3, 5, 7, 9, every three cycles [12 weeks] thereafter up to end of treatment [up to 3.6 years overall]) (cycle length = 28 days)
    Notes
    [39] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.
    Justification: Only Phase II arms were planned to be included in the analysis.
    End point values
    Phase II: Ipatasertib 400 mg + Abiraterone Phase II: Ipatasertib 200 mg + Abiraterone Phase II: Placebo + Abiraterone
    Number of subjects analysed
    1
    4
    1
    Units: months
        median (confidence interval 90%)
    8.77 (0.0000 to 99999)
    9999 (0.99 to 99999)
    9999 (0.0000 to 99999)
    Statistical analysis title
    Ipatasertib 200 mg v Placebo
    Comparison groups
    Phase II: Ipatasertib 200 mg + Abiraterone v Phase II: Placebo + Abiraterone
    Number of subjects included in analysis
    5
    Analysis specification
    Pre-specified
    Analysis type
    superiority
    P-value
    = 0.6171
    Method
    Logrank
    Parameter type
    Hazard ratio (HR)
    Point estimate
    999.99
    Confidence interval
         level
    90%
         sides
    2-sided
         lower limit
    0
         upper limit
    99999
    Statistical analysis title
    Ipatasertib 400 mg v Placebo
    Comparison groups
    Phase II: Ipatasertib 400 mg + Abiraterone v Phase II: Placebo + Abiraterone
    Number of subjects included in analysis
    2
    Analysis specification
    Pre-specified
    Analysis type
    superiority
    P-value
    = 0.3173
    Method
    Logrank
    Parameter type
    Hazard ratio (HR)
    Point estimate
    999.99
    Confidence interval
         level
    90%
         sides
    2-sided
         lower limit
    0
         upper limit
    99999

    Secondary: Phase II: Percentage of Participants With CTC Reduction Response in Participants With ICR PTEN Loss

    Close Top of page
    End point title
    Phase II: Percentage of Participants With CTC Reduction Response in Participants With ICR PTEN Loss [40]
    End point description
    CTC reduction response was defined as participants with a reduction in CTCs of ≥ 30% compared to baseline. PTEN status was assessed by RUO IHC assay that was performed at ICR, UK. Samples with 100% of the tumor with no PTEN staining were classified as “ICR PTEN loss”. Number of participants analyzed=participants with PTEN loss and CTC > 0 cells/7.5 mL at baseline.
    End point type
    Secondary
    End point timeframe
    Baseline, on Day 1 of Cycle 2, on Day 1 of Cycle 3, and at the treatment completion visit (up to overall 3.6 years) (cycle length=28 days)
    Notes
    [40] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.
    Justification: Only Phase II arms were planned to be included in the analysis.
    End point values
    Phase II: Ipatasertib 400 mg + Abiraterone Phase II: Ipatasertib 200 mg + Abiraterone Phase II: Placebo + Abiraterone
    Number of subjects analysed
    20
    20
    17
    Units: percentage of participants
        number (confidence interval 90%)
    75.0 (55.80 to 87.42)
    75.0 (55.80 to 87.42)
    70.6 (50.00 to 85.95)
    Statistical analysis title
    Ipatasertib 400 mg v Placebo
    Comparison groups
    Phase II: Ipatasertib 400 mg + Abiraterone v Phase II: Placebo + Abiraterone
    Number of subjects included in analysis
    37
    Analysis specification
    Pre-specified
    Analysis type
    superiority
    P-value
    = 0.7633
    Method
    Chi-squared
    Parameter type
    Difference in response rates
    Point estimate
    4.41
    Confidence interval
         level
    90%
         sides
    2-sided
         lower limit
    -19.76
         upper limit
    28.58
    Statistical analysis title
    Ipatasertib 200 mg v Placebo
    Comparison groups
    Phase II: Ipatasertib 200 mg + Abiraterone v Phase II: Placebo + Abiraterone
    Number of subjects included in analysis
    37
    Analysis specification
    Pre-specified
    Analysis type
    superiority
    P-value
    = 0.7633
    Method
    Chi-squared
    Parameter type
    Difference in response rates
    Point estimate
    4.41
    Confidence interval
         level
    90%
         sides
    2-sided
         lower limit
    -19.76
         upper limit
    28.58

    Secondary: Phase II: Percentage of Participants With CTC Conversion - ITT Population

    Close Top of page
    End point title
    Phase II: Percentage of Participants With CTC Conversion - ITT Population [41]
    End point description
    CTC conversion was defined as a decline to < 5 cells/7.5 milliliter (mL) post baseline among participants with CTC ≥ 5 cells/7.5 mL at baseline. The ITT Population was defined as all randomised participants with the participants allocated to the treatment arm according to the randomisation. Number of participants analysed=participants with CTC ≥ 5 cells/7.5 mL at baseline.
    End point type
    Secondary
    End point timeframe
    Baseline, on Day 1 of Cycle 2, on Day 1 of Cycle 3, and at the treatment completion visit (up to overall 3.6 years) (cycle length=28 days)
    Notes
    [41] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.
    Justification: Only Phase II arms were planned to be included in the analysis.
    End point values
    Phase II: Ipatasertib 400 mg + Abiraterone Phase II: Ipatasertib 200 mg + Abiraterone Phase II: Placebo + Abiraterone
    Number of subjects analysed
    41
    47
    48
    Units: percentage of participants
        number (confidence interval 90%)
    43.9 (31.18 to 57.87)
    46.8 (34.48 to 59.72)
    41.7 (29.59 to 54.55)
    Statistical analysis title
    Ipatasertib 200 mg v Placebo
    Comparison groups
    Phase II: Ipatasertib 200 mg + Abiraterone v Phase II: Placebo + Abiraterone
    Number of subjects included in analysis
    95
    Analysis specification
    Pre-specified
    Analysis type
    superiority
    P-value
    = 0.6139
    Method
    Chi-squared
    Parameter type
    Difference in response rates
    Point estimate
    5.14
    Confidence interval
         level
    90%
         sides
    2-sided
         lower limit
    -11.6
         upper limit
    21.88
    Statistical analysis title
    Ipatasertib 400 mg v Placebo
    Comparison groups
    Phase II: Ipatasertib 400 mg + Abiraterone v Phase II: Placebo + Abiraterone
    Number of subjects included in analysis
    89
    Analysis specification
    Pre-specified
    Analysis type
    superiority
    P-value
    = 0.8317
    Method
    Chi-squared
    Parameter type
    Difference in response rates
    Point estimate
    2.24
    Confidence interval
         level
    90%
         sides
    2-sided
         lower limit
    -15.07
         upper limit
    19.54

    Secondary: Phase II: Percentage of Participants With Pain Progression in Participants With ICR PTEN Loss

    Close Top of page
    End point title
    Phase II: Percentage of Participants With Pain Progression in Participants With ICR PTEN Loss [42]
    End point description
    Pain progression was defined as ≥ 2 point-increase from baseline on the modified Brief Pain Inventory – short form (mBPI-sf). The mBPI-sf consists of four questions that assess pain intensity (worst, least, average, right now) and seven items within one question that assess the impact of pain on daily functions (general activity, mood, walking ability, normal work, relations with other people, sleep, enjoyment of life). Each item was assessed on 0-10 scale with 0 being no pain to 10 being worst imaginable pain. Total score was the average of individual item (range 0-10). PTEN status was assessed by RUO IHC assay that was performed at ICR, UK. Samples with 100% of the tumor with no PTEN staining were classified as “ICR PTEN loss”. Number of participants analyzed=participants with PTEN loss.
    End point type
    Secondary
    End point timeframe
    Screening, Day 1 of each cycle (cycle length=28 days) up to treatment completion (up to 3.6 years)
    Notes
    [42] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.
    Justification: Only Phase II arms were planned to be included in the analysis.
    End point values
    Phase II: Ipatasertib 400 mg + Abiraterone Phase II: Ipatasertib 200 mg + Abiraterone Phase II: Placebo + Abiraterone
    Number of subjects analysed
    25
    25
    21
    Units: percentage of participants
        number (not applicable)
    40.0
    28.0
    33.3
    No statistical analyses for this end point

    Secondary: Phase II: Percentage of Participants With Pain Progression - ITT Population

    Close Top of page
    End point title
    Phase II: Percentage of Participants With Pain Progression - ITT Population [43]
    End point description
    Pain progression was defined as ≥ 2 point-increase from baseline on the modified Brief Pain Inventory – short form (mBPI-sf). The mBPI-sf consists of four questions that assess pain intensity (worst, least, average, right now) and seven items within one question that assess the impact of pain on daily functions (general activity, mood, walking ability, normal work, relations with other people, sleep, enjoyment of life). Each item was assessed on 0-10 scale with 0 being no pain to 10 being worst imaginable pain. Total score was the average of individual item (range 0-10). The ITT Population was defined as all randomised participants with the participants allocated to the treatment arm according to the randomisation.
    End point type
    Secondary
    End point timeframe
    Screening, Day 1 of each cycle (cycle length=28 days) up to treatment completion (up to 3.6 years)
    Notes
    [43] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.
    Justification: Only Phase II arms were planned to be included in the analysis.
    End point values
    Phase II: Ipatasertib 400 mg + Abiraterone Phase II: Ipatasertib 200 mg + Abiraterone Phase II: Placebo + Abiraterone
    Number of subjects analysed
    84
    86
    83
    Units: percentage of participants
        number (not applicable)
    33.3
    34.9
    34.9
    No statistical analyses for this end point

    Secondary: Phase II: Percentage of Participants With CTC Conversion in Participants With ICR PTEN Loss

    Close Top of page
    End point title
    Phase II: Percentage of Participants With CTC Conversion in Participants With ICR PTEN Loss [44]
    End point description
    CTC conversion was defined as a decline to < 5 cells/7.5 milliliter (mL) post baseline among participants with CTC ≥ 5 cells/7.5 mL at baseline. PTEN status was assessed by RUO IHC assay that was performed at ICR, UK. Samples with 100% of the tumor with no PTEN staining were classified as “ICR PTEN loss”. Number of participants analyzed=participants with PTEN loss and CTC ≥ 5 cells/7.5 mL at baseline.
    End point type
    Secondary
    End point timeframe
    Baseline, on Day 1 of Cycle 2, on Day 1 of Cycle 3, and at the treatment completion visit (up to overall 3.6 years) (cycle length=28 days)
    Notes
    [44] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.
    Justification: Only Phase II arms were planned to be included in the analysis.
    End point values
    Phase II: Ipatasertib 400 mg + Abiraterone Phase II: Ipatasertib 200 mg + Abiraterone Phase II: Placebo + Abiraterone
    Number of subjects analysed
    12
    18
    22
    Units: percentage of participants
        number (confidence interval 90%)
    66.7 (39.84 to 84.58)
    22.2 (10.60 to 41.88)
    31.8 (18.11 to 50.00)
    Statistical analysis title
    Ipatasertib 200 mg v Placebo
    Comparison groups
    Phase II: Ipatasertib 200 mg + Abiraterone v Phase II: Placebo + Abiraterone
    Number of subjects included in analysis
    40
    Analysis specification
    Pre-specified
    Analysis type
    superiority
    P-value
    = 0.4989
    Method
    Chi-squared
    Parameter type
    Difference in response rates
    Point estimate
    -9.6
    Confidence interval
         level
    90%
         sides
    2-sided
         lower limit
    -32.54
         upper limit
    13.35
    Statistical analysis title
    Ipatasertib 400 mg v Placebo
    Comparison groups
    Phase II: Ipatasertib 400 mg + Abiraterone v Phase II: Placebo + Abiraterone
    Number of subjects included in analysis
    34
    Analysis specification
    Pre-specified
    Analysis type
    superiority
    P-value
    = 0.0505
    Method
    Chi-squared
    Parameter type
    Difference in response rates
    Point estimate
    34.85
    Confidence interval
         level
    90%
         sides
    2-sided
         lower limit
    7.14
         upper limit
    62.56

    Secondary: Phase II: Time to Pain Progression in Participants With ICR PTEN Loss

    Close Top of page
    End point title
    Phase II: Time to Pain Progression in Participants With ICR PTEN Loss [45]
    End point description
    Time to pain progression was defined as the time from screening till first occurrence of pain progression. Pain progression: ≥ 2 point-increase from baseline on the modified Brief Pain Inventory – short form (mBPI-sf). The mBPI-sf consists of 4questions that assess pain intensity (worst, least, average, right now) and seven items within one question that assess the impact of pain on daily functions (general activity, mood, walking ability, normal work, relations with other people, sleep, enjoyment of life). Each item was assessed on 0-10 scale with 0 being no pain to 10 being worst imaginable pain. Total score was the average of individual item (range 0-10). PTEN status was assessed by RUO IHC assay that was performed at ICR, UK. Samples with 100% of the tumor with no PTEN staining were classified as “ICR PTEN loss”. Number of participants analyzed=participants with PTEN loss. Here, "99999" reflects that the data was not evaluable because of insufficient number of events.
    End point type
    Secondary
    End point timeframe
    Screening, Day 1 of each cycle (cycle length=28 days) up to treatment completion (up to 3.6 years)
    Notes
    [45] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.
    Justification: Only Phase II arms were planned to be included in the analysis.
    End point values
    Phase II: Ipatasertib 400 mg + Abiraterone Phase II: Ipatasertib 200 mg + Abiraterone Phase II: Placebo + Abiraterone
    Number of subjects analysed
    25
    25
    21
    Units: months
        median (confidence interval 90%)
    16.49 (7.59 to 16.49)
    99999 (8.28 to 99999)
    6.93 (5.65 to 99999)
    Statistical analysis title
    Unstratified analysis:Ipatasertib 200 mg v Placebo
    Comparison groups
    Phase II: Ipatasertib 200 mg + Abiraterone v Phase II: Placebo + Abiraterone
    Number of subjects included in analysis
    46
    Analysis specification
    Pre-specified
    Analysis type
    superiority
    P-value
    = 0.7383
    Method
    Logrank
    Parameter type
    Hazard ratio (HR)
    Point estimate
    0.84
    Confidence interval
         level
    90%
         sides
    2-sided
         lower limit
    0.35
         upper limit
    2.02
    Statistical analysis title
    Unstratified analysis:Ipatasertib 400 mg v Placebo
    Comparison groups
    Phase II: Ipatasertib 400 mg + Abiraterone v Phase II: Placebo + Abiraterone
    Number of subjects included in analysis
    46
    Analysis specification
    Pre-specified
    Analysis type
    superiority
    P-value
    = 0.8271
    Method
    Logrank
    Parameter type
    Hazard ratio (HR)
    Point estimate
    0.89
    Confidence interval
         level
    90%
         sides
    2-sided
         lower limit
    0.39
         upper limit
    2.06

    Secondary: Phase II: Time to Pain Progression - ITT Population

    Close Top of page
    End point title
    Phase II: Time to Pain Progression - ITT Population [46]
    End point description
    Time to pain progression was defined as the time from screening till first occurrence of pain progression. Pain progression was defined as ≥ 2 point-increase from baseline on the modified Brief Pain Inventory – short form (mBPI-sf). The mBPI-sf consists of four questions that assess pain intensity (worst, least, average, right now) and seven items within one question that assess the impact of pain on daily functions (general activity, mood, walking ability, normal work, relations with other people, sleep, enjoyment of life). Each item was assessed on 0-10 scale with 0 being no pain to 10 being worst imaginable pain. Total score was the average of individual item (range 0-10). The ITT Population was defined as all randomised participants with the participants allocated to the treatment arm according to the randomisation. Here, "99999" reflects that the data was not evaluable because of insufficient number of events.
    End point type
    Secondary
    End point timeframe
    Screening, Day 1 of each cycle (cycle length=28 days) up to treatment completion (up to 3.6 years)
    Notes
    [46] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.
    Justification: Only Phase II arms were planned to be included in the analysis.
    End point values
    Phase II: Ipatasertib 400 mg + Abiraterone Phase II: Ipatasertib 200 mg + Abiraterone Phase II: Placebo + Abiraterone
    Number of subjects analysed
    84
    86
    83
    Units: months
        median (confidence interval 90%)
    13.90 (8.61 to 99999)
    16.16 (8.54 to 99999)
    15.15 (11.07 to 99999)
    Statistical analysis title
    Unstratified analysis:Ipatasertib 400 mg v Placebo
    Comparison groups
    Phase II: Ipatasertib 400 mg + Abiraterone v Phase II: Placebo + Abiraterone
    Number of subjects included in analysis
    167
    Analysis specification
    Pre-specified
    Analysis type
    superiority
    P-value
    = 0.8483
    Method
    Logrank
    Parameter type
    Hazard ratio (HR)
    Point estimate
    0.95
    Confidence interval
         level
    90%
         sides
    2-sided
         lower limit
    0.61
         upper limit
    1.47
    Statistical analysis title
    Stratified analysis:Ipatasertib 200 mg v Placebo
    Statistical analysis description
    Strata were: prior enzalutamide (Yes vs. No), progression factor (PSA only vs. other), and number of prior chemotherapy regimens for metastatic disease (one vs. more than one).
    Comparison groups
    Phase II: Ipatasertib 200 mg + Abiraterone v Phase II: Placebo + Abiraterone
    Number of subjects included in analysis
    169
    Analysis specification
    Pre-specified
    Analysis type
    superiority
    P-value
    = 0.8647
    Method
    Logrank
    Parameter type
    Hazard ratio (HR)
    Point estimate
    1.05
    Confidence interval
         level
    90%
         sides
    2-sided
         lower limit
    0.67
         upper limit
    1.63
    Statistical analysis title
    Stratified analysis:Ipatasertib 400 mg v Placebo
    Statistical analysis description
    Strata were: prior enzalutamide (Yes vs. No), progression factor (PSA only vs. other), and number of prior chemotherapy regimens for metastatic disease (one vs. more than one).
    Comparison groups
    Phase II: Ipatasertib 400 mg + Abiraterone v Phase II: Placebo + Abiraterone
    Number of subjects included in analysis
    167
    Analysis specification
    Pre-specified
    Analysis type
    superiority
    P-value
    = 0.8847
    Method
    Logrank
    Parameter type
    Hazard ratio (HR)
    Point estimate
    1.04
    Confidence interval
         level
    90%
         sides
    2-sided
         lower limit
    0.66
         upper limit
    1.65
    Statistical analysis title
    Unstratified analysis:Ipatasertib 200 mg v Placebo
    Comparison groups
    Phase II: Ipatasertib 200 mg + Abiraterone v Phase II: Placebo + Abiraterone
    Number of subjects included in analysis
    169
    Analysis specification
    Pre-specified
    Analysis type
    superiority
    P-value
    = 0.785
    Method
    Logrank
    Parameter type
    Hazard ratio (HR)
    Point estimate
    1.08
    Confidence interval
         level
    90%
         sides
    2-sided
         lower limit
    0.7
         upper limit
    1.65

    Secondary: Phase II: Percentage of Participants With Adverse Events (AEs)

    Close Top of page
    End point title
    Phase II: Percentage of Participants With Adverse Events (AEs)
    End point description
    An Adverse Event (AE) was defined as any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. The Safety Population was defined as all participants who had received ipatasertib, apitolisib, placebo, or abiraterone treatment.
    End point type
    Secondary
    End point timeframe
    Baseline up until 30 days following the last administration of study treatment or until initiation of another anti-cancer therapy, whichever occurred first (up to approximately 8.9 years)
    End point values
    Safety Set Ipatasertib 400 mg + Abiraterone Safety Set Ipatasertib 200 mg + Abiraterone Safety Set Placebo + Abiraterone
    Number of subjects analysed
    84
    88
    81
    Units: percentage of participants
        number (not applicable)
    98.8
    96.6
    93.8
    No statistical analyses for this end point

    Secondary: Phase II: Ipatasertib Plasma Concentrations When Co-Administered With Abiraterone

    Close Top of page
    End point title
    Phase II: Ipatasertib Plasma Concentrations When Co-Administered With Abiraterone [47]
    End point description
    The Pharmacokinetic (PK) Analysis Population was defined as all participants who had evaluable PK data. Data were only analyzed in ipatasertib treatment arms. Total number analyzed represents all participants with evaluations at one or more time points. Here, "n" signifies the number of participants with PK data available for specified timepoint.
    End point type
    Secondary
    End point timeframe
    Phase II: Cycle 1, Day 1: 1, 4 hours postdose; Cycle 1, Day 15: predose, 2, 4 hours postdose; Cycle 2, Day 1: predose, 1-4 hours postdose (cycle length = 28 days)
    Notes
    [47] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.
    Justification: Only the arms treated with ipatasertib in Phase II were planned to be included in the analysis.
    End point values
    Phase II: Ipatasertib 400 mg + Abiraterone Phase II: Ipatasertib 200 mg + Abiraterone
    Number of subjects analysed
    83
    86
    Units: ng/mL
    geometric mean (geometric coefficient of variation)
        Cycle 1, Day 1: 1 hour postdose (n=43, 47)
    101 ( 359.5 )
    63.4 ( 187.2 )
        Cycle 1, Day 1: 4 hours postdose (n=72, 76)
    180 ( 103.4 )
    87.0 ( 71.6 )
        Cycle 1, Day 15: predose (n=74, 81)
    53.1 ( 97.2 )
    24.5 ( 61.9 )
        Cycle 1, Day 15: 2 hours postdose (n=69, 77)
    213 ( 174.3 )
    140 ( 103.7 )
        Cycle 1, Day 15: 4 hours postdose (n=72, 77)
    272 ( 137.9 )
    139 ( 69.3 )
        Cycle 2, Day 1: predose (n=73, 82)
    46.7 ( 138.6 )
    25.3 ( 49.8 )
        Cycle 2, Day 1: 1-4 hours postdose (n=70, 82)
    243 ( 94.4 )
    145 ( 80.9 )
    No statistical analyses for this end point

    Secondary: Phase II: G-037720 (Metabolite of Ipatasertib) Plasma Concentrations

    Close Top of page
    End point title
    Phase II: G-037720 (Metabolite of Ipatasertib) Plasma Concentrations [48]
    End point description
    The Pharmacokinetic (PK) Analysis Population was defined as all participants who had evaluable PK data. Data were only analyzed in ipatasertib treatment arms. Total number analyzed represents all participants with evaluations at one or more time points. Here, "n" signifies the number of participants with PK data available for specified timepoint.
    End point type
    Secondary
    End point timeframe
    Phase II: Cycle 1, Day 1: 1, 4 hours postdose; Cycle 1, Day 15: predose, 2, 4 hours postdose; Cycle 2, Day 1: predose, 1-4 hours postdose (cycle length = 28 days)
    Notes
    [48] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.
    Justification: Only the arms treated with ipatasertib in Phase II were planned to be included in the analysis.
    End point values
    Phase II: Ipatasertib 400 mg + Abiraterone Phase II: Ipatasertib 200 mg + Abiraterone
    Number of subjects analysed
    82
    86
    Units: ng/mL
    geometric mean (geometric coefficient of variation)
        Cycle 1, Day 1: 1 hour postdose (n=35, 40)
    34.7 ( 223.1 )
    13.9 ( 268.9 )
        Cycle 1, Day 1: 4 hours postdose (n=69, 75)
    101 ( 61.8 )
    42.9 ( 96.6 )
        Cycle 1, Day 15: predose (n=73, 80)
    44.1 ( 92.4 )
    20.4 ( 59.2 )
        Cycle 1, Day 15: 2 hours postdose (n=69, 77)
    121 ( 159.4 )
    78.0 ( 93.0 )
        Cycle 1, Day 15: 4 hours postdose (n=72, 76)
    178 ( 134.0 )
    101 ( 61.0 )
    No statistical analyses for this end point

    Adverse events

    Close Top of page
    Adverse events information
    Timeframe for reporting adverse events
    Baseline up until 30 days following the last administration of study treatment or until initiation of another anti-cancer therapy, whichever occurred first (up to approximately 10.7 years)
    Adverse event reporting additional description
    The Safety Population was defined as all participants who had received ipatasertib, apitolisib, placebo, or abiraterone treatment.
    Assessment type
    Non-systematic
    Dictionary used for adverse event reporting
    Dictionary name
    MedDRA
    Dictionary version
    23.1, 25.1
    Reporting groups
    Reporting group title
    Phase Ib: Ipatasertib 400 mg
    Reporting group description
    Participants received ipatasertib 400 mg orally daily, abiraterone 1000 mg orally daily, and prednisone/prednisolone 5 mg bid orally continuously in 28-day treatment cycles until disease progression or intolerable toxicity.

    Reporting group title
    Phase Ib: Apitolisib 30 mg
    Reporting group description
    Participants received apitolisib 30 mg orally daily, abiraterone 1000 mg orally daily, and prednisone/prednisolone 5 mg bid orally continuously in 28-day treatment cycles until disease progression or intolerable toxicity.

    Reporting group title
    Phase II: Ipatasertib 400 mg + Abiraterone
    Reporting group description
    Participants received ipatasertib 400 mg orally daily, abiraterone 1000 mg orally daily, and prednisone/prednisolone 5 mg bid orally continuously in 28-day treatment cycles until disease progression or intolerable toxicity.

    Reporting group title
    Phase II: Ipatasertib 200 mg + Abiraterone
    Reporting group description
    Participants received ipatasertib 200 mg orally daily, abiraterone 1000 mg orally daily, and prednisone/prednisolone 5 mg bid orally continuously in 28-day treatment cycles until disease progression or intolerable toxicity.

    Reporting group title
    Phase II: Placebo + Abiraterone
    Reporting group description
    Participants received placebo (for ipatasertib 400 mg or 200) orally daily, abiraterone 1000 mg orally daily, and prednisone/prednisolone 5 mg bid orally continuously in 28-day treatment cycles until disease progression or intolerable toxicity.

    Reporting group title
    Safety Cohort: Ipatasertib 400 mg + Abiraterone
    Reporting group description
    Participants received ipatasertib 400 mg orally once daily and/or prednisone/prednisolone 5 mg orally once daily or bid and/or abiraterone 1000 mg orally once daily according to the following schedule: ipatasertib in the morning during Cycle 1, Days 1-7; ipatasertib in the morning plus prednisone/prednisolone once at night during Cycle 1, Day 8; ipatasertib in the morning plus prednisone/prednisolone bid (morning and night) during Cycle 1, Days 9-11; ipatasertib in the morning plus prednisone/prednisolone bid (morning and night) and abiraterone in the morning during Cycle 1, Days 12-18; ipatasertib in the evening plus prednisone/prednisolone bid (morning and night) and abiraterone at the same time as ipatasertib during Cycle 1, Days 19-25; Cycle 2 and beyond ipatasertib once daily in the morning or evening, abiraterone at the same time as ipatasertib, and prednisone/prednisolone bid.

    Serious adverse events
    Phase Ib: Ipatasertib 400 mg Phase Ib: Apitolisib 30 mg Phase II: Ipatasertib 400 mg + Abiraterone Phase II: Ipatasertib 200 mg + Abiraterone Phase II: Placebo + Abiraterone Safety Cohort: Ipatasertib 400 mg + Abiraterone
    Total subjects affected by serious adverse events
         subjects affected / exposed
    9 / 14 (64.29%)
    5 / 6 (83.33%)
    43 / 84 (51.19%)
    42 / 88 (47.73%)
    18 / 81 (22.22%)
    6 / 25 (24.00%)
         number of deaths (all causes)
    1
    0
    67
    72
    67
    2
         number of deaths resulting from adverse events
    0
    0
    0
    0
    0
    0
    Neoplasms benign, malignant and unspecified (incl cysts and polyps)
    Prostate cancer
         subjects affected / exposed
    1 / 14 (7.14%)
    1 / 6 (16.67%)
    3 / 84 (3.57%)
    2 / 88 (2.27%)
    0 / 81 (0.00%)
    1 / 25 (4.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 1
    0 / 3
    0 / 2
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 1
    0 / 1
    0 / 3
    0 / 2
    0 / 0
    0 / 1
    Prostatic adenoma
         subjects affected / exposed
    0 / 14 (0.00%)
    0 / 6 (0.00%)
    1 / 84 (1.19%)
    0 / 88 (0.00%)
    0 / 81 (0.00%)
    0 / 25 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 1
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Small cell carcinoma
         subjects affected / exposed
    0 / 14 (0.00%)
    0 / 6 (0.00%)
    1 / 84 (1.19%)
    0 / 88 (0.00%)
    0 / 81 (0.00%)
    0 / 25 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 1
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Squamous cell carcinoma of skin
         subjects affected / exposed
    0 / 14 (0.00%)
    0 / 6 (0.00%)
    1 / 84 (1.19%)
    0 / 88 (0.00%)
    0 / 81 (0.00%)
    0 / 25 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 1
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Vascular disorders
    Hypotension
         subjects affected / exposed
    0 / 14 (0.00%)
    1 / 6 (16.67%)
    0 / 84 (0.00%)
    0 / 88 (0.00%)
    0 / 81 (0.00%)
    0 / 25 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 2
    0 / 0
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Deep vein thrombosis
         subjects affected / exposed
    0 / 14 (0.00%)
    0 / 6 (0.00%)
    0 / 84 (0.00%)
    1 / 88 (1.14%)
    0 / 81 (0.00%)
    0 / 25 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 1
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Aortic aneurysm rupture
         subjects affected / exposed
    0 / 14 (0.00%)
    0 / 6 (0.00%)
    0 / 84 (0.00%)
    1 / 88 (1.14%)
    0 / 81 (0.00%)
    0 / 25 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 1
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 1
    0 / 0
    0 / 0
    Thrombosis
         subjects affected / exposed
    0 / 14 (0.00%)
    0 / 6 (0.00%)
    1 / 84 (1.19%)
    0 / 88 (0.00%)
    0 / 81 (0.00%)
    0 / 25 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 1
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Pelvic venous thrombosis
         subjects affected / exposed
    0 / 14 (0.00%)
    0 / 6 (0.00%)
    0 / 84 (0.00%)
    1 / 88 (1.14%)
    0 / 81 (0.00%)
    0 / 25 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 1
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    General disorders and administration site conditions
    Fatigue
         subjects affected / exposed
    0 / 14 (0.00%)
    0 / 6 (0.00%)
    0 / 84 (0.00%)
    0 / 88 (0.00%)
    1 / 81 (1.23%)
    0 / 25 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    1 / 2
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Disease progression
         subjects affected / exposed
    0 / 14 (0.00%)
    0 / 6 (0.00%)
    0 / 84 (0.00%)
    2 / 88 (2.27%)
    0 / 81 (0.00%)
    0 / 25 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 2
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 2
    0 / 1
    0 / 0
    Death
         subjects affected / exposed
    0 / 14 (0.00%)
    0 / 6 (0.00%)
    0 / 84 (0.00%)
    1 / 88 (1.14%)
    1 / 81 (1.23%)
    0 / 25 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 1
    0 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 1
    0 / 1
    0 / 0
    Asthenia
         subjects affected / exposed
    0 / 14 (0.00%)
    0 / 6 (0.00%)
    1 / 84 (1.19%)
    0 / 88 (0.00%)
    0 / 81 (0.00%)
    1 / 25 (4.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 1
    0 / 0
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    General physical health deterioration
         subjects affected / exposed
    0 / 14 (0.00%)
    0 / 6 (0.00%)
    1 / 84 (1.19%)
    1 / 88 (1.14%)
    0 / 81 (0.00%)
    0 / 25 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 1
    0 / 1
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Pain
         subjects affected / exposed
    1 / 14 (7.14%)
    0 / 6 (0.00%)
    2 / 84 (2.38%)
    1 / 88 (1.14%)
    0 / 81 (0.00%)
    0 / 25 (0.00%)
         occurrences causally related to treatment / all
    0 / 2
    0 / 0
    0 / 3
    0 / 1
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Pyrexia
         subjects affected / exposed
    0 / 14 (0.00%)
    0 / 6 (0.00%)
    1 / 84 (1.19%)
    2 / 88 (2.27%)
    0 / 81 (0.00%)
    0 / 25 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 1
    0 / 2
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Malaise
         subjects affected / exposed
    0 / 14 (0.00%)
    0 / 6 (0.00%)
    1 / 84 (1.19%)
    0 / 88 (0.00%)
    0 / 81 (0.00%)
    0 / 25 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 1
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Reproductive system and breast disorders
    Prostatitis
         subjects affected / exposed
    0 / 14 (0.00%)
    0 / 6 (0.00%)
    1 / 84 (1.19%)
    0 / 88 (0.00%)
    0 / 81 (0.00%)
    0 / 25 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 1
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Pelvic pain
         subjects affected / exposed
    0 / 14 (0.00%)
    0 / 6 (0.00%)
    0 / 84 (0.00%)
    1 / 88 (1.14%)
    1 / 81 (1.23%)
    0 / 25 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 1
    0 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Respiratory, thoracic and mediastinal disorders
    Interstitial lung disease
         subjects affected / exposed
    0 / 14 (0.00%)
    0 / 6 (0.00%)
    1 / 84 (1.19%)
    0 / 88 (0.00%)
    0 / 81 (0.00%)
    0 / 25 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    1 / 1
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Dyspnoea
         subjects affected / exposed
    0 / 14 (0.00%)
    0 / 6 (0.00%)
    1 / 84 (1.19%)
    1 / 88 (1.14%)
    0 / 81 (0.00%)
    0 / 25 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 1
    0 / 1
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Chronic obstructive pulmonary disease
         subjects affected / exposed
    0 / 14 (0.00%)
    0 / 6 (0.00%)
    1 / 84 (1.19%)
    0 / 88 (0.00%)
    0 / 81 (0.00%)
    0 / 25 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 1
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Pneumonitis
         subjects affected / exposed
    0 / 14 (0.00%)
    0 / 6 (0.00%)
    0 / 84 (0.00%)
    0 / 88 (0.00%)
    1 / 81 (1.23%)
    0 / 25 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Acute pulmonary oedema
         subjects affected / exposed
    0 / 14 (0.00%)
    0 / 6 (0.00%)
    0 / 84 (0.00%)
    1 / 88 (1.14%)
    0 / 81 (0.00%)
    0 / 25 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 1
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Psychiatric disorders
    Confusional state
         subjects affected / exposed
    0 / 14 (0.00%)
    0 / 6 (0.00%)
    1 / 84 (1.19%)
    0 / 88 (0.00%)
    0 / 81 (0.00%)
    1 / 25 (4.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 1
    0 / 0
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Investigations
    Haematocrit decreased
         subjects affected / exposed
    1 / 14 (7.14%)
    0 / 6 (0.00%)
    0 / 84 (0.00%)
    0 / 88 (0.00%)
    0 / 81 (0.00%)
    0 / 25 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Aspartate aminotransferase increased
         subjects affected / exposed
    1 / 14 (7.14%)
    0 / 6 (0.00%)
    0 / 84 (0.00%)
    0 / 88 (0.00%)
    0 / 81 (0.00%)
    0 / 25 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Haemoglobin decreased
         subjects affected / exposed
    1 / 14 (7.14%)
    0 / 6 (0.00%)
    0 / 84 (0.00%)
    0 / 88 (0.00%)
    0 / 81 (0.00%)
    0 / 25 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Injury, poisoning and procedural complications
    Subdural haematoma
         subjects affected / exposed
    1 / 14 (7.14%)
    0 / 6 (0.00%)
    0 / 84 (0.00%)
    0 / 88 (0.00%)
    0 / 81 (0.00%)
    0 / 25 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Skull fracture
         subjects affected / exposed
    0 / 14 (0.00%)
    0 / 6 (0.00%)
    0 / 84 (0.00%)
    1 / 88 (1.14%)
    0 / 81 (0.00%)
    0 / 25 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 1
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Radius fracture
         subjects affected / exposed
    0 / 14 (0.00%)
    0 / 6 (0.00%)
    0 / 84 (0.00%)
    1 / 88 (1.14%)
    0 / 81 (0.00%)
    0 / 25 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 2
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Ulna fracture
         subjects affected / exposed
    0 / 14 (0.00%)
    0 / 6 (0.00%)
    0 / 84 (0.00%)
    1 / 88 (1.14%)
    0 / 81 (0.00%)
    0 / 25 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 1
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Upper limb fracture
         subjects affected / exposed
    0 / 14 (0.00%)
    0 / 6 (0.00%)
    0 / 84 (0.00%)
    1 / 88 (1.14%)
    0 / 81 (0.00%)
    0 / 25 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 1
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Accidental overdose
         subjects affected / exposed
    0 / 14 (0.00%)
    0 / 6 (0.00%)
    0 / 84 (0.00%)
    1 / 88 (1.14%)
    0 / 81 (0.00%)
    0 / 25 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 1
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Fall
         subjects affected / exposed
    0 / 14 (0.00%)
    0 / 6 (0.00%)
    0 / 84 (0.00%)
    1 / 88 (1.14%)
    1 / 81 (1.23%)
    0 / 25 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 1
    0 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Rib fracture
         subjects affected / exposed
    0 / 14 (0.00%)
    0 / 6 (0.00%)
    0 / 84 (0.00%)
    0 / 88 (0.00%)
    1 / 81 (1.23%)
    0 / 25 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Road traffic accident
         subjects affected / exposed
    0 / 14 (0.00%)
    0 / 6 (0.00%)
    0 / 84 (0.00%)
    0 / 88 (0.00%)
    0 / 81 (0.00%)
    1 / 25 (4.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Multiple fractures
         subjects affected / exposed
    0 / 14 (0.00%)
    0 / 6 (0.00%)
    0 / 84 (0.00%)
    0 / 88 (0.00%)
    0 / 81 (0.00%)
    1 / 25 (4.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Cardiac disorders
    Atrioventricular block
         subjects affected / exposed
    0 / 14 (0.00%)
    0 / 6 (0.00%)
    1 / 84 (1.19%)
    0 / 88 (0.00%)
    0 / 81 (0.00%)
    0 / 25 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 1
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Atrial fibrillation
         subjects affected / exposed
    0 / 14 (0.00%)
    0 / 6 (0.00%)
    1 / 84 (1.19%)
    0 / 88 (0.00%)
    0 / 81 (0.00%)
    0 / 25 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 1
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Bradycardia
         subjects affected / exposed
    0 / 14 (0.00%)
    0 / 6 (0.00%)
    1 / 84 (1.19%)
    0 / 88 (0.00%)
    0 / 81 (0.00%)
    0 / 25 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 1
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 1
    0 / 0
    0 / 0
    0 / 0
    Cardiac failure acute
         subjects affected / exposed
    0 / 14 (0.00%)
    0 / 6 (0.00%)
    0 / 84 (0.00%)
    0 / 88 (0.00%)
    1 / 81 (1.23%)
    0 / 25 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 1
    0 / 0
    Cardiac failure
         subjects affected / exposed
    0 / 14 (0.00%)
    0 / 6 (0.00%)
    0 / 84 (0.00%)
    1 / 88 (1.14%)
    0 / 81 (0.00%)
    0 / 25 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 1
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Supraventricular tachycardia
         subjects affected / exposed
    0 / 14 (0.00%)
    0 / 6 (0.00%)
    0 / 84 (0.00%)
    0 / 88 (0.00%)
    1 / 81 (1.23%)
    0 / 25 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Left ventricular failure
         subjects affected / exposed
    0 / 14 (0.00%)
    0 / 6 (0.00%)
    0 / 84 (0.00%)
    1 / 88 (1.14%)
    0 / 81 (0.00%)
    0 / 25 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    1 / 1
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Nervous system disorders
    Cerebral haemorrhage
         subjects affected / exposed
    0 / 14 (0.00%)
    0 / 6 (0.00%)
    0 / 84 (0.00%)
    0 / 88 (0.00%)
    1 / 81 (1.23%)
    0 / 25 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 1
    0 / 0
    Dizziness
         subjects affected / exposed
    0 / 14 (0.00%)
    0 / 6 (0.00%)
    0 / 84 (0.00%)
    1 / 88 (1.14%)
    0 / 81 (0.00%)
    0 / 25 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    1 / 1
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Ischaemic stroke
         subjects affected / exposed
    0 / 14 (0.00%)
    0 / 6 (0.00%)
    0 / 84 (0.00%)
    0 / 88 (0.00%)
    1 / 81 (1.23%)
    0 / 25 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Nervous system disorder
         subjects affected / exposed
    0 / 14 (0.00%)
    0 / 6 (0.00%)
    1 / 84 (1.19%)
    0 / 88 (0.00%)
    0 / 81 (0.00%)
    0 / 25 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 1
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 1
    0 / 0
    0 / 0
    0 / 0
    Spinal cord compression
         subjects affected / exposed
    0 / 14 (0.00%)
    0 / 6 (0.00%)
    1 / 84 (1.19%)
    1 / 88 (1.14%)
    1 / 81 (1.23%)
    0 / 25 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 1
    0 / 1
    0 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Syncope
         subjects affected / exposed
    0 / 14 (0.00%)
    0 / 6 (0.00%)
    1 / 84 (1.19%)
    0 / 88 (0.00%)
    0 / 81 (0.00%)
    0 / 25 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 1
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Vascular encephalopathy
         subjects affected / exposed
    0 / 14 (0.00%)
    0 / 6 (0.00%)
    0 / 84 (0.00%)
    1 / 88 (1.14%)
    0 / 81 (0.00%)
    0 / 25 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 1
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Cerebral haematoma
         subjects affected / exposed
    0 / 14 (0.00%)
    0 / 6 (0.00%)
    0 / 84 (0.00%)
    1 / 88 (1.14%)
    0 / 81 (0.00%)
    0 / 25 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 1
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Blood and lymphatic system disorders
    Coagulopathy
         subjects affected / exposed
    1 / 14 (7.14%)
    0 / 6 (0.00%)
    0 / 84 (0.00%)
    0 / 88 (0.00%)
    0 / 81 (0.00%)
    0 / 25 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Anaemia
         subjects affected / exposed
    0 / 14 (0.00%)
    0 / 6 (0.00%)
    1 / 84 (1.19%)
    2 / 88 (2.27%)
    1 / 81 (1.23%)
    0 / 25 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 1
    0 / 2
    0 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Haemolytic uraemic syndrome
         subjects affected / exposed
    0 / 14 (0.00%)
    0 / 6 (0.00%)
    1 / 84 (1.19%)
    0 / 88 (0.00%)
    0 / 81 (0.00%)
    0 / 25 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 1
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Eye disorders
    Chorioretinopathy
         subjects affected / exposed
    0 / 14 (0.00%)
    0 / 6 (0.00%)
    0 / 84 (0.00%)
    1 / 88 (1.14%)
    0 / 81 (0.00%)
    0 / 25 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 1
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Gastrointestinal disorders
    Colitis
         subjects affected / exposed
    1 / 14 (7.14%)
    0 / 6 (0.00%)
    0 / 84 (0.00%)
    0 / 88 (0.00%)
    0 / 81 (0.00%)
    0 / 25 (0.00%)
         occurrences causally related to treatment / all
    1 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Constipation
         subjects affected / exposed
    0 / 14 (0.00%)
    0 / 6 (0.00%)
    0 / 84 (0.00%)
    0 / 88 (0.00%)
    1 / 81 (1.23%)
    0 / 25 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    1 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Ascites
         subjects affected / exposed
    0 / 14 (0.00%)
    0 / 6 (0.00%)
    0 / 84 (0.00%)
    1 / 88 (1.14%)
    0 / 81 (0.00%)
    0 / 25 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 1
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Abdominal pain upper
         subjects affected / exposed
    0 / 14 (0.00%)
    0 / 6 (0.00%)
    0 / 84 (0.00%)
    0 / 88 (0.00%)
    1 / 81 (1.23%)
    0 / 25 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Abdominal pain
         subjects affected / exposed
    0 / 14 (0.00%)
    0 / 6 (0.00%)
    0 / 84 (0.00%)
    2 / 88 (2.27%)
    0 / 81 (0.00%)
    0 / 25 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 2
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Diarrhoea
         subjects affected / exposed
    2 / 14 (14.29%)
    0 / 6 (0.00%)
    2 / 84 (2.38%)
    1 / 88 (1.14%)
    0 / 81 (0.00%)
    0 / 25 (0.00%)
         occurrences causally related to treatment / all
    2 / 2
    0 / 0
    2 / 2
    0 / 1
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Dyspepsia
         subjects affected / exposed
    0 / 14 (0.00%)
    0 / 6 (0.00%)
    0 / 84 (0.00%)
    0 / 88 (0.00%)
    1 / 81 (1.23%)
    0 / 25 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Lower gastrointestinal haemorrhage
         subjects affected / exposed
    0 / 14 (0.00%)
    0 / 6 (0.00%)
    0 / 84 (0.00%)
    1 / 88 (1.14%)
    0 / 81 (0.00%)
    0 / 25 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 1
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Haematochezia
         subjects affected / exposed
    0 / 14 (0.00%)
    0 / 6 (0.00%)
    1 / 84 (1.19%)
    0 / 88 (0.00%)
    0 / 81 (0.00%)
    0 / 25 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 1
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Gastrointestinal haemorrhage
         subjects affected / exposed
    0 / 14 (0.00%)
    0 / 6 (0.00%)
    0 / 84 (0.00%)
    1 / 88 (1.14%)
    0 / 81 (0.00%)
    0 / 25 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 1
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Enterocolitis
         subjects affected / exposed
    0 / 14 (0.00%)
    0 / 6 (0.00%)
    0 / 84 (0.00%)
    0 / 88 (0.00%)
    1 / 81 (1.23%)
    0 / 25 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Enteritis
         subjects affected / exposed
    0 / 14 (0.00%)
    0 / 6 (0.00%)
    1 / 84 (1.19%)
    0 / 88 (0.00%)
    0 / 81 (0.00%)
    0 / 25 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 1
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Dysphagia
         subjects affected / exposed
    0 / 14 (0.00%)
    0 / 6 (0.00%)
    0 / 84 (0.00%)
    0 / 88 (0.00%)
    1 / 81 (1.23%)
    0 / 25 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Nausea
         subjects affected / exposed
    0 / 14 (0.00%)
    0 / 6 (0.00%)
    0 / 84 (0.00%)
    0 / 88 (0.00%)
    1 / 81 (1.23%)
    0 / 25 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 2
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Vomiting
         subjects affected / exposed
    0 / 14 (0.00%)
    0 / 6 (0.00%)
    0 / 84 (0.00%)
    0 / 88 (0.00%)
    1 / 81 (1.23%)
    0 / 25 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 2
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Pharyngo-oesophageal diverticulum
         subjects affected / exposed
    0 / 14 (0.00%)
    0 / 6 (0.00%)
    0 / 84 (0.00%)
    0 / 88 (0.00%)
    1 / 81 (1.23%)
    0 / 25 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Upper gastrointestinal haemorrhage
         subjects affected / exposed
    0 / 14 (0.00%)
    0 / 6 (0.00%)
    1 / 84 (1.19%)
    0 / 88 (0.00%)
    0 / 81 (0.00%)
    0 / 25 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 1
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Faecaloma
         subjects affected / exposed
    0 / 14 (0.00%)
    0 / 6 (0.00%)
    0 / 84 (0.00%)
    1 / 88 (1.14%)
    0 / 81 (0.00%)
    0 / 25 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 1
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Intestinal obstruction
         subjects affected / exposed
    0 / 14 (0.00%)
    0 / 6 (0.00%)
    1 / 84 (1.19%)
    0 / 88 (0.00%)
    0 / 81 (0.00%)
    0 / 25 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 1
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Skin and subcutaneous tissue disorders
    Toxic skin eruption
         subjects affected / exposed
    0 / 14 (0.00%)
    0 / 6 (0.00%)
    1 / 84 (1.19%)
    1 / 88 (1.14%)
    0 / 81 (0.00%)
    0 / 25 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    1 / 1
    1 / 1
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Rash maculo-papular
         subjects affected / exposed
    1 / 14 (7.14%)
    2 / 6 (33.33%)
    0 / 84 (0.00%)
    0 / 88 (0.00%)
    0 / 81 (0.00%)
    1 / 25 (4.00%)
         occurrences causally related to treatment / all
    1 / 1
    2 / 2
    0 / 0
    0 / 0
    0 / 0
    1 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Rash
         subjects affected / exposed
    0 / 14 (0.00%)
    0 / 6 (0.00%)
    2 / 84 (2.38%)
    0 / 88 (0.00%)
    0 / 81 (0.00%)
    1 / 25 (4.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    2 / 2
    0 / 0
    0 / 0
    1 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Decubitus ulcer
         subjects affected / exposed
    0 / 14 (0.00%)
    0 / 6 (0.00%)
    0 / 84 (0.00%)
    0 / 88 (0.00%)
    0 / 81 (0.00%)
    1 / 25 (4.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Renal and urinary disorders
    Acute kidney injury
         subjects affected / exposed
    0 / 14 (0.00%)
    0 / 6 (0.00%)
    1 / 84 (1.19%)
    0 / 88 (0.00%)
    1 / 81 (1.23%)
    0 / 25 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 1
    0 / 0
    0 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Calculus urinary
         subjects affected / exposed
    0 / 14 (0.00%)
    0 / 6 (0.00%)
    1 / 84 (1.19%)
    0 / 88 (0.00%)
    0 / 81 (0.00%)
    0 / 25 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 1
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Haematuria
         subjects affected / exposed
    0 / 14 (0.00%)
    0 / 6 (0.00%)
    2 / 84 (2.38%)
    1 / 88 (1.14%)
    1 / 81 (1.23%)
    1 / 25 (4.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 2
    0 / 2
    0 / 1
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Nephrolithiasis
         subjects affected / exposed
    0 / 14 (0.00%)
    0 / 6 (0.00%)
    1 / 84 (1.19%)
    0 / 88 (0.00%)
    0 / 81 (0.00%)
    1 / 25 (4.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 1
    0 / 0
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Nephropathy toxic
         subjects affected / exposed
    0 / 14 (0.00%)
    0 / 6 (0.00%)
    0 / 84 (0.00%)
    1 / 88 (1.14%)
    0 / 81 (0.00%)
    0 / 25 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 1
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Renal failure
         subjects affected / exposed
    0 / 14 (0.00%)
    0 / 6 (0.00%)
    1 / 84 (1.19%)
    1 / 88 (1.14%)
    1 / 81 (1.23%)
    0 / 25 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 1
    1 / 1
    0 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Ureteric obstruction
         subjects affected / exposed
    0 / 14 (0.00%)
    0 / 6 (0.00%)
    0 / 84 (0.00%)
    1 / 88 (1.14%)
    0 / 81 (0.00%)
    0 / 25 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 1
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Urinary retention
         subjects affected / exposed
    0 / 14 (0.00%)
    0 / 6 (0.00%)
    1 / 84 (1.19%)
    2 / 88 (2.27%)
    0 / 81 (0.00%)
    0 / 25 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 1
    0 / 2
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Bladder perforation
         subjects affected / exposed
    0 / 14 (0.00%)
    0 / 6 (0.00%)
    0 / 84 (0.00%)
    1 / 88 (1.14%)
    0 / 81 (0.00%)
    0 / 25 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 1
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Ureterolithiasis
         subjects affected / exposed
    0 / 14 (0.00%)
    0 / 6 (0.00%)
    1 / 84 (1.19%)
    0 / 88 (0.00%)
    0 / 81 (0.00%)
    0 / 25 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 2
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Ureteric stenosis
         subjects affected / exposed
    0 / 14 (0.00%)
    0 / 6 (0.00%)
    1 / 84 (1.19%)
    0 / 88 (0.00%)
    0 / 81 (0.00%)
    0 / 25 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 1
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Renal colic
         subjects affected / exposed
    0 / 14 (0.00%)
    0 / 6 (0.00%)
    1 / 84 (1.19%)
    0 / 88 (0.00%)
    0 / 81 (0.00%)
    0 / 25 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 1
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Musculoskeletal and connective tissue disorders
    Back pain
         subjects affected / exposed
    1 / 14 (7.14%)
    0 / 6 (0.00%)
    1 / 84 (1.19%)
    2 / 88 (2.27%)
    1 / 81 (1.23%)
    0 / 25 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
    0 / 1
    0 / 3
    0 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Bone pain
         subjects affected / exposed
    0 / 14 (0.00%)
    0 / 6 (0.00%)
    1 / 84 (1.19%)
    1 / 88 (1.14%)
    0 / 81 (0.00%)
    0 / 25 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 1
    0 / 1
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Osteolysis
         subjects affected / exposed
    0 / 14 (0.00%)
    0 / 6 (0.00%)
    0 / 84 (0.00%)
    1 / 88 (1.14%)
    0 / 81 (0.00%)
    0 / 25 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 1
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Spinal pain
         subjects affected / exposed
    0 / 14 (0.00%)
    0 / 6 (0.00%)
    1 / 84 (1.19%)
    0 / 88 (0.00%)
    0 / 81 (0.00%)
    0 / 25 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 2
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Haematoma muscle
         subjects affected / exposed
    0 / 14 (0.00%)
    0 / 6 (0.00%)
    1 / 84 (1.19%)
    0 / 88 (0.00%)
    0 / 81 (0.00%)
    0 / 25 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 1
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Arthralgia
         subjects affected / exposed
    0 / 14 (0.00%)
    0 / 6 (0.00%)
    0 / 84 (0.00%)
    1 / 88 (1.14%)
    0 / 81 (0.00%)
    0 / 25 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 1
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Musculoskeletal chest pain
         subjects affected / exposed
    0 / 14 (0.00%)
    0 / 6 (0.00%)
    0 / 84 (0.00%)
    1 / 88 (1.14%)
    0 / 81 (0.00%)
    0 / 25 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 1
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Pain in extremity
         subjects affected / exposed
    0 / 14 (0.00%)
    0 / 6 (0.00%)
    1 / 84 (1.19%)
    0 / 88 (0.00%)
    0 / 81 (0.00%)
    0 / 25 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    1 / 1
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Infections and infestations
    Pyelonephritis
         subjects affected / exposed
    0 / 14 (0.00%)
    0 / 6 (0.00%)
    0 / 84 (0.00%)
    1 / 88 (1.14%)
    0 / 81 (0.00%)
    0 / 25 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 1
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Pneumonia
         subjects affected / exposed
    2 / 14 (14.29%)
    1 / 6 (16.67%)
    3 / 84 (3.57%)
    5 / 88 (5.68%)
    0 / 81 (0.00%)
    0 / 25 (0.00%)
         occurrences causally related to treatment / all
    1 / 2
    0 / 1
    1 / 3
    0 / 6
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Osteomyelitis
         subjects affected / exposed
    0 / 14 (0.00%)
    0 / 6 (0.00%)
    1 / 84 (1.19%)
    0 / 88 (0.00%)
    0 / 81 (0.00%)
    0 / 25 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 2
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Gastroenteritis
         subjects affected / exposed
    0 / 14 (0.00%)
    0 / 6 (0.00%)
    0 / 84 (0.00%)
    1 / 88 (1.14%)
    0 / 81 (0.00%)
    0 / 25 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 1
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Cellulitis
         subjects affected / exposed
    0 / 14 (0.00%)
    0 / 6 (0.00%)
    0 / 84 (0.00%)
    1 / 88 (1.14%)
    0 / 81 (0.00%)
    0 / 25 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 1
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Sepsis
         subjects affected / exposed
    0 / 14 (0.00%)
    0 / 6 (0.00%)
    0 / 84 (0.00%)
    3 / 88 (3.41%)
    0 / 81 (0.00%)
    1 / 25 (4.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 3
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 2
    0 / 0
    0 / 0
    Respiratory tract infection
         subjects affected / exposed
    0 / 14 (0.00%)
    0 / 6 (0.00%)
    1 / 84 (1.19%)
    0 / 88 (0.00%)
    0 / 81 (0.00%)
    0 / 25 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 1
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Pyelonephritis acute
         subjects affected / exposed
    0 / 14 (0.00%)
    0 / 6 (0.00%)
    0 / 84 (0.00%)
    1 / 88 (1.14%)
    0 / 81 (0.00%)
    0 / 25 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 1
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Septic shock
         subjects affected / exposed
    0 / 14 (0.00%)
    0 / 6 (0.00%)
    0 / 84 (0.00%)
    2 / 88 (2.27%)
    0 / 81 (0.00%)
    0 / 25 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 2
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Spinal cord infection
         subjects affected / exposed
    0 / 14 (0.00%)
    0 / 6 (0.00%)
    0 / 84 (0.00%)
    0 / 88 (0.00%)
    1 / 81 (1.23%)
    0 / 25 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Urinary tract infection
         subjects affected / exposed
    0 / 14 (0.00%)
    0 / 6 (0.00%)
    5 / 84 (5.95%)
    1 / 88 (1.14%)
    1 / 81 (1.23%)
    1 / 25 (4.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 6
    0 / 2
    1 / 1
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Urosepsis
         subjects affected / exposed
    0 / 14 (0.00%)
    0 / 6 (0.00%)
    1 / 84 (1.19%)
    0 / 88 (0.00%)
    0 / 81 (0.00%)
    1 / 25 (4.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 1
    0 / 0
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Vascular device infection
         subjects affected / exposed
    0 / 14 (0.00%)
    0 / 6 (0.00%)
    0 / 84 (0.00%)
    1 / 88 (1.14%)
    0 / 81 (0.00%)
    0 / 25 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 1
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Tuberculosis
         subjects affected / exposed
    0 / 14 (0.00%)
    0 / 6 (0.00%)
    1 / 84 (1.19%)
    0 / 88 (0.00%)
    0 / 81 (0.00%)
    0 / 25 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    1 / 1
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Metabolism and nutrition disorders
    Hypokalaemia
         subjects affected / exposed
    0 / 14 (0.00%)
    0 / 6 (0.00%)
    1 / 84 (1.19%)
    0 / 88 (0.00%)
    1 / 81 (1.23%)
    0 / 25 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    1 / 1
    0 / 0
    1 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Hypoglycaemia
         subjects affected / exposed
    0 / 14 (0.00%)
    0 / 6 (0.00%)
    1 / 84 (1.19%)
    0 / 88 (0.00%)
    0 / 81 (0.00%)
    0 / 25 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    1 / 1
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Hyperglycaemia
         subjects affected / exposed
    1 / 14 (7.14%)
    2 / 6 (33.33%)
    2 / 84 (2.38%)
    1 / 88 (1.14%)
    0 / 81 (0.00%)
    0 / 25 (0.00%)
         occurrences causally related to treatment / all
    1 / 1
    0 / 2
    2 / 2
    1 / 1
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Dehydration
         subjects affected / exposed
    0 / 14 (0.00%)
    0 / 6 (0.00%)
    1 / 84 (1.19%)
    1 / 88 (1.14%)
    1 / 81 (1.23%)
    0 / 25 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    2 / 2
    0 / 1
    0 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Diabetes mellitus inadequate control
         subjects affected / exposed
    0 / 14 (0.00%)
    0 / 6 (0.00%)
    1 / 84 (1.19%)
    0 / 88 (0.00%)
    0 / 81 (0.00%)
    0 / 25 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 1
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Failure to thrive
         subjects affected / exposed
    1 / 14 (7.14%)
    0 / 6 (0.00%)
    0 / 84 (0.00%)
    0 / 88 (0.00%)
    0 / 81 (0.00%)
    0 / 25 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Ketoacidosis
         subjects affected / exposed
    0 / 14 (0.00%)
    0 / 6 (0.00%)
    1 / 84 (1.19%)
    0 / 88 (0.00%)
    0 / 81 (0.00%)
    0 / 25 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    1 / 1
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Malnutrition
         subjects affected / exposed
    0 / 14 (0.00%)
    0 / 6 (0.00%)
    0 / 84 (0.00%)
    0 / 88 (0.00%)
    0 / 81 (0.00%)
    1 / 25 (4.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Diabetic metabolic decompensation
         subjects affected / exposed
    0 / 14 (0.00%)
    0 / 6 (0.00%)
    0 / 84 (0.00%)
    0 / 88 (0.00%)
    1 / 81 (1.23%)
    0 / 25 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    1 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Frequency threshold for reporting non-serious adverse events: 5%
    Non-serious adverse events
    Phase Ib: Ipatasertib 400 mg Phase Ib: Apitolisib 30 mg Phase II: Ipatasertib 400 mg + Abiraterone Phase II: Ipatasertib 200 mg + Abiraterone Phase II: Placebo + Abiraterone Safety Cohort: Ipatasertib 400 mg + Abiraterone
    Total subjects affected by non serious adverse events
         subjects affected / exposed
    14 / 14 (100.00%)
    6 / 6 (100.00%)
    82 / 84 (97.62%)
    79 / 88 (89.77%)
    76 / 81 (93.83%)
    25 / 25 (100.00%)
    Vascular disorders
    Hot flush
         subjects affected / exposed
    1 / 14 (7.14%)
    1 / 6 (16.67%)
    10 / 84 (11.90%)
    5 / 88 (5.68%)
    7 / 81 (8.64%)
    0 / 25 (0.00%)
         occurrences all number
    1
    1
    10
    5
    7
    0
    Hypertension
         subjects affected / exposed
    1 / 14 (7.14%)
    0 / 6 (0.00%)
    11 / 84 (13.10%)
    12 / 88 (13.64%)
    9 / 81 (11.11%)
    1 / 25 (4.00%)
         occurrences all number
    1
    0
    15
    13
    12
    1
    Hypotension
         subjects affected / exposed
    1 / 14 (7.14%)
    1 / 6 (16.67%)
    3 / 84 (3.57%)
    1 / 88 (1.14%)
    1 / 81 (1.23%)
    0 / 25 (0.00%)
         occurrences all number
    1
    1
    3
    1
    1
    0
    General disorders and administration site conditions
    Fatigue
         subjects affected / exposed
    9 / 14 (64.29%)
    1 / 6 (16.67%)
    22 / 84 (26.19%)
    25 / 88 (28.41%)
    24 / 81 (29.63%)
    5 / 25 (20.00%)
         occurrences all number
    11
    1
    36
    37
    32
    7
    Asthenia
         subjects affected / exposed
    4 / 14 (28.57%)
    1 / 6 (16.67%)
    23 / 84 (27.38%)
    20 / 88 (22.73%)
    13 / 81 (16.05%)
    2 / 25 (8.00%)
         occurrences all number
    4
    1
    36
    24
    15
    4
    Gait disturbance
         subjects affected / exposed
    1 / 14 (7.14%)
    0 / 6 (0.00%)
    0 / 84 (0.00%)
    1 / 88 (1.14%)
    1 / 81 (1.23%)
    0 / 25 (0.00%)
         occurrences all number
    1
    0
    0
    1
    1
    0
    Mucosal inflammation
         subjects affected / exposed
    3 / 14 (21.43%)
    0 / 6 (0.00%)
    3 / 84 (3.57%)
    1 / 88 (1.14%)
    1 / 81 (1.23%)
    0 / 25 (0.00%)
         occurrences all number
    3
    0
    4
    1
    1
    0
    Thirst
         subjects affected / exposed
    0 / 14 (0.00%)
    1 / 6 (16.67%)
    0 / 84 (0.00%)
    0 / 88 (0.00%)
    0 / 81 (0.00%)
    0 / 25 (0.00%)
         occurrences all number
    0
    1
    0
    0
    0
    0
    Pyrexia
         subjects affected / exposed
    1 / 14 (7.14%)
    3 / 6 (50.00%)
    12 / 84 (14.29%)
    12 / 88 (13.64%)
    9 / 81 (11.11%)
    4 / 25 (16.00%)
         occurrences all number
    1
    3
    28
    16
    13
    5
    Pain
         subjects affected / exposed
    0 / 14 (0.00%)
    1 / 6 (16.67%)
    7 / 84 (8.33%)
    9 / 88 (10.23%)
    2 / 81 (2.47%)
    1 / 25 (4.00%)
         occurrences all number
    0
    1
    7
    14
    2
    1
    Oedema peripheral
         subjects affected / exposed
    1 / 14 (7.14%)
    0 / 6 (0.00%)
    10 / 84 (11.90%)
    9 / 88 (10.23%)
    7 / 81 (8.64%)
    0 / 25 (0.00%)
         occurrences all number
    2
    0
    13
    11
    7
    0
    Oedema
         subjects affected / exposed
    1 / 14 (7.14%)
    0 / 6 (0.00%)
    1 / 84 (1.19%)
    1 / 88 (1.14%)
    0 / 81 (0.00%)
    1 / 25 (4.00%)
         occurrences all number
    1
    0
    1
    1
    0
    1
    Reproductive system and breast disorders
    Penile pain
         subjects affected / exposed
    1 / 14 (7.14%)
    0 / 6 (0.00%)
    0 / 84 (0.00%)
    0 / 88 (0.00%)
    0 / 81 (0.00%)
    0 / 25 (0.00%)
         occurrences all number
    1
    0
    0
    0
    0
    0
    Pelvic pain
         subjects affected / exposed
    0 / 14 (0.00%)
    0 / 6 (0.00%)
    7 / 84 (8.33%)
    5 / 88 (5.68%)
    0 / 81 (0.00%)
    1 / 25 (4.00%)
         occurrences all number
    0
    0
    8
    7
    0
    1
    Respiratory, thoracic and mediastinal disorders
    Dry throat
         subjects affected / exposed
    0 / 14 (0.00%)
    1 / 6 (16.67%)
    0 / 84 (0.00%)
    0 / 88 (0.00%)
    0 / 81 (0.00%)
    0 / 25 (0.00%)
         occurrences all number
    0
    1
    0
    0
    0
    0
    Cough
         subjects affected / exposed
    1 / 14 (7.14%)
    0 / 6 (0.00%)
    7 / 84 (8.33%)
    6 / 88 (6.82%)
    7 / 81 (8.64%)
    1 / 25 (4.00%)
         occurrences all number
    1
    0
    13
    7
    7
    1
    Dysphonia
         subjects affected / exposed
    0 / 14 (0.00%)
    1 / 6 (16.67%)
    1 / 84 (1.19%)
    2 / 88 (2.27%)
    0 / 81 (0.00%)
    0 / 25 (0.00%)
         occurrences all number
    0
    1
    1
    3
    0
    0
    Dyspnoea exertional
         subjects affected / exposed
    1 / 14 (7.14%)
    0 / 6 (0.00%)
    1 / 84 (1.19%)
    0 / 88 (0.00%)
    0 / 81 (0.00%)
    0 / 25 (0.00%)
         occurrences all number
    1
    0
    1
    0
    0
    0
    Dyspnoea
         subjects affected / exposed
    0 / 14 (0.00%)
    1 / 6 (16.67%)
    11 / 84 (13.10%)
    9 / 88 (10.23%)
    6 / 81 (7.41%)
    3 / 25 (12.00%)
         occurrences all number
    0
    1
    13
    10
    7
    5
    Oropharyngeal pain
         subjects affected / exposed
    2 / 14 (14.29%)
    1 / 6 (16.67%)
    3 / 84 (3.57%)
    2 / 88 (2.27%)
    1 / 81 (1.23%)
    1 / 25 (4.00%)
         occurrences all number
    2
    1
    3
    2
    1
    1
    Wheezing
         subjects affected / exposed
    0 / 14 (0.00%)
    1 / 6 (16.67%)
    1 / 84 (1.19%)
    0 / 88 (0.00%)
    0 / 81 (0.00%)
    0 / 25 (0.00%)
         occurrences all number
    0
    1
    1
    0
    0
    0
    Sinus congestion
         subjects affected / exposed
    0 / 14 (0.00%)
    1 / 6 (16.67%)
    1 / 84 (1.19%)
    0 / 88 (0.00%)
    0 / 81 (0.00%)
    0 / 25 (0.00%)
         occurrences all number
    0
    1
    1
    0
    0
    0
    Rhinorrhoea
         subjects affected / exposed
    1 / 14 (7.14%)
    1 / 6 (16.67%)
    2 / 84 (2.38%)
    4 / 88 (4.55%)
    2 / 81 (2.47%)
    0 / 25 (0.00%)
         occurrences all number
    1
    1
    2
    4
    4
    0
    Pleural effusion
         subjects affected / exposed
    1 / 14 (7.14%)
    0 / 6 (0.00%)
    0 / 84 (0.00%)
    1 / 88 (1.14%)
    0 / 81 (0.00%)
    0 / 25 (0.00%)
         occurrences all number
    1
    0
    0
    1
    0
    0
    Psychiatric disorders
    Restlessness
         subjects affected / exposed
    1 / 14 (7.14%)
    0 / 6 (0.00%)
    0 / 84 (0.00%)
    0 / 88 (0.00%)
    0 / 81 (0.00%)
    0 / 25 (0.00%)
         occurrences all number
    1
    0
    0
    0
    0
    0
    Insomnia
         subjects affected / exposed
    0 / 14 (0.00%)
    0 / 6 (0.00%)
    9 / 84 (10.71%)
    10 / 88 (11.36%)
    5 / 81 (6.17%)
    2 / 25 (8.00%)
         occurrences all number
    0
    0
    11
    10
    5
    2
    Depression
         subjects affected / exposed
    2 / 14 (14.29%)
    0 / 6 (0.00%)
    3 / 84 (3.57%)
    3 / 88 (3.41%)
    1 / 81 (1.23%)
    1 / 25 (4.00%)
         occurrences all number
    2
    0
    3
    3
    1
    1
    Anxiety
         subjects affected / exposed
    1 / 14 (7.14%)
    0 / 6 (0.00%)
    3 / 84 (3.57%)
    5 / 88 (5.68%)
    3 / 81 (3.70%)
    2 / 25 (8.00%)
         occurrences all number
    1
    0
    3
    5
    3
    2
    Agitation
         subjects affected / exposed
    1 / 14 (7.14%)
    0 / 6 (0.00%)
    0 / 84 (0.00%)
    0 / 88 (0.00%)
    1 / 81 (1.23%)
    0 / 25 (0.00%)
         occurrences all number
    1
    0
    0
    0
    1
    0
    Investigations
    Blood alkaline phosphatase increased
         subjects affected / exposed
    2 / 14 (14.29%)
    0 / 6 (0.00%)
    2 / 84 (2.38%)
    0 / 88 (0.00%)
    1 / 81 (1.23%)
    1 / 25 (4.00%)
         occurrences all number
    2
    0
    2
    0
    1
    1
    Aspartate aminotransferase increased
         subjects affected / exposed
    1 / 14 (7.14%)
    0 / 6 (0.00%)
    5 / 84 (5.95%)
    4 / 88 (4.55%)
    1 / 81 (1.23%)
    3 / 25 (12.00%)
         occurrences all number
    1
    0
    8
    5
    1
    10
    Blood urine present
         subjects affected / exposed
    1 / 14 (7.14%)
    0 / 6 (0.00%)
    0 / 84 (0.00%)
    0 / 88 (0.00%)
    0 / 81 (0.00%)
    0 / 25 (0.00%)
         occurrences all number
    1
    0
    0
    0
    0
    0
    Blood creatinine increased
         subjects affected / exposed
    0 / 14 (0.00%)
    0 / 6 (0.00%)
    7 / 84 (8.33%)
    4 / 88 (4.55%)
    1 / 81 (1.23%)
    1 / 25 (4.00%)
         occurrences all number
    0
    0
    7
    5
    2
    1
    Weight decreased
         subjects affected / exposed
    0 / 14 (0.00%)
    0 / 6 (0.00%)
    3 / 84 (3.57%)
    3 / 88 (3.41%)
    1 / 81 (1.23%)
    3 / 25 (12.00%)
         occurrences all number
    0
    0
    6
    4
    1
    3
    Blood triglycerides increased
         subjects affected / exposed
    0 / 14 (0.00%)
    0 / 6 (0.00%)
    1 / 84 (1.19%)
    0 / 88 (0.00%)
    0 / 81 (0.00%)
    2 / 25 (8.00%)
         occurrences all number
    0
    0
    1
    0
    0
    2
    Alanine aminotransferase increased
         subjects affected / exposed
    0 / 14 (0.00%)
    0 / 6 (0.00%)
    4 / 84 (4.76%)
    2 / 88 (2.27%)
    1 / 81 (1.23%)
    3 / 25 (12.00%)
         occurrences all number
    0
    0
    8
    2
    1
    12
    Injury, poisoning and procedural complications
    Meniscus injury
         subjects affected / exposed
    1 / 14 (7.14%)
    0 / 6 (0.00%)
    0 / 84 (0.00%)
    0 / 88 (0.00%)
    0 / 81 (0.00%)
    0 / 25 (0.00%)
         occurrences all number
    1
    0
    0
    0
    0
    0
    Fall
         subjects affected / exposed
    0 / 14 (0.00%)
    0 / 6 (0.00%)
    1 / 84 (1.19%)
    2 / 88 (2.27%)
    3 / 81 (3.70%)
    3 / 25 (12.00%)
         occurrences all number
    0
    0
    1
    4
    3
    3
    Nervous system disorders
    Dysgeusia
         subjects affected / exposed
    1 / 14 (7.14%)
    0 / 6 (0.00%)
    6 / 84 (7.14%)
    0 / 88 (0.00%)
    3 / 81 (3.70%)
    2 / 25 (8.00%)
         occurrences all number
    1
    0
    8
    0
    3
    2
    Dizziness
         subjects affected / exposed
    3 / 14 (21.43%)
    0 / 6 (0.00%)
    11 / 84 (13.10%)
    6 / 88 (6.82%)
    5 / 81 (6.17%)
    1 / 25 (4.00%)
         occurrences all number
    4
    0
    16
    8
    5
    1
    Somnolence
         subjects affected / exposed
    1 / 14 (7.14%)
    0 / 6 (0.00%)
    3 / 84 (3.57%)
    2 / 88 (2.27%)
    0 / 81 (0.00%)
    0 / 25 (0.00%)
         occurrences all number
    1
    0
    3
    2
    0
    0
    Lethargy
         subjects affected / exposed
    0 / 14 (0.00%)
    1 / 6 (16.67%)
    1 / 84 (1.19%)
    1 / 88 (1.14%)
    1 / 81 (1.23%)
    0 / 25 (0.00%)
         occurrences all number
    0
    1
    1
    1
    1
    0
    Hypoaesthesia
         subjects affected / exposed
    2 / 14 (14.29%)
    0 / 6 (0.00%)
    0 / 84 (0.00%)
    1 / 88 (1.14%)
    1 / 81 (1.23%)
    0 / 25 (0.00%)
         occurrences all number
    2
    0
    0
    9
    1
    0
    Headache
         subjects affected / exposed
    2 / 14 (14.29%)
    0 / 6 (0.00%)
    9 / 84 (10.71%)
    5 / 88 (5.68%)
    6 / 81 (7.41%)
    1 / 25 (4.00%)
         occurrences all number
    3
    0
    14
    5
    9
    1
    Paraesthesia
         subjects affected / exposed
    0 / 14 (0.00%)
    0 / 6 (0.00%)
    3 / 84 (3.57%)
    5 / 88 (5.68%)
    3 / 81 (3.70%)
    0 / 25 (0.00%)
         occurrences all number
    0
    0
    3
    9
    3
    0
    Taste disorder
         subjects affected / exposed
    1 / 14 (7.14%)
    0 / 6 (0.00%)
    0 / 84 (0.00%)
    0 / 88 (0.00%)
    0 / 81 (0.00%)
    0 / 25 (0.00%)
         occurrences all number
    1
    0
    0
    0
    0
    0
    Tremor
         subjects affected / exposed
    0 / 14 (0.00%)
    0 / 6 (0.00%)
    0 / 84 (0.00%)
    1 / 88 (1.14%)
    0 / 81 (0.00%)
    2 / 25 (8.00%)
         occurrences all number
    0
    0
    0
    1
    0
    2
    Blood and lymphatic system disorders
    Anaemia
         subjects affected / exposed
    2 / 14 (14.29%)
    1 / 6 (16.67%)
    19 / 84 (22.62%)
    18 / 88 (20.45%)
    8 / 81 (9.88%)
    2 / 25 (8.00%)
         occurrences all number
    2
    1
    25
    37
    13
    4
    Pancytopenia
         subjects affected / exposed
    0 / 14 (0.00%)
    1 / 6 (16.67%)
    0 / 84 (0.00%)
    0 / 88 (0.00%)
    0 / 81 (0.00%)
    0 / 25 (0.00%)
         occurrences all number
    0
    1
    0
    0
    0
    0
    Eye disorders
    Vision blurred
         subjects affected / exposed
    1 / 14 (7.14%)
    0 / 6 (0.00%)
    0 / 84 (0.00%)
    1 / 88 (1.14%)
    3 / 81 (3.70%)
    0 / 25 (0.00%)
         occurrences all number
    1
    0
    0
    1
    4
    0
    Gastrointestinal disorders
    Dry mouth
         subjects affected / exposed
    2 / 14 (14.29%)
    1 / 6 (16.67%)
    3 / 84 (3.57%)
    0 / 88 (0.00%)
    4 / 81 (4.94%)
    0 / 25 (0.00%)
         occurrences all number
    2
    1
    3
    0
    4
    0
    Diarrhoea
         subjects affected / exposed
    9 / 14 (64.29%)
    4 / 6 (66.67%)
    65 / 84 (77.38%)
    42 / 88 (47.73%)
    20 / 81 (24.69%)
    17 / 25 (68.00%)
         occurrences all number
    14
    6
    198
    72
    36
    63
    Constipation
         subjects affected / exposed
    1 / 14 (7.14%)
    2 / 6 (33.33%)
    8 / 84 (9.52%)
    18 / 88 (20.45%)
    16 / 81 (19.75%)
    0 / 25 (0.00%)
         occurrences all number
    1
    2
    8
    26
    22
    0
    Cheilosis
         subjects affected / exposed
    1 / 14 (7.14%)
    0 / 6 (0.00%)
    0 / 84 (0.00%)
    0 / 88 (0.00%)
    0 / 81 (0.00%)
    0 / 25 (0.00%)
         occurrences all number
    1
    0
    0
    0
    0
    0
    Abdominal pain lower
         subjects affected / exposed
    0 / 14 (0.00%)
    1 / 6 (16.67%)
    2 / 84 (2.38%)
    2 / 88 (2.27%)
    0 / 81 (0.00%)
    0 / 25 (0.00%)
         occurrences all number
    0
    1
    3
    2
    0
    0
    Abdominal pain
         subjects affected / exposed
    1 / 14 (7.14%)
    0 / 6 (0.00%)
    9 / 84 (10.71%)
    10 / 88 (11.36%)
    3 / 81 (3.70%)
    2 / 25 (8.00%)
         occurrences all number
    1
    0
    12
    13
    3
    2
    Abdominal pain upper
         subjects affected / exposed
    0 / 14 (0.00%)
    0 / 6 (0.00%)
    8 / 84 (9.52%)
    4 / 88 (4.55%)
    5 / 81 (6.17%)
    0 / 25 (0.00%)
         occurrences all number
    0
    0
    10
    5
    7
    0
    Vomiting
         subjects affected / exposed
    9 / 14 (64.29%)
    3 / 6 (50.00%)
    27 / 84 (32.14%)
    24 / 88 (27.27%)
    12 / 81 (14.81%)
    5 / 25 (20.00%)
         occurrences all number
    14
    3
    42
    69
    24
    12
    Tongue discolouration
         subjects affected / exposed
    0 / 14 (0.00%)
    1 / 6 (16.67%)
    0 / 84 (0.00%)
    0 / 88 (0.00%)
    0 / 81 (0.00%)
    0 / 25 (0.00%)
         occurrences all number
    0
    1
    0
    0
    0
    0
    Retching
         subjects affected / exposed
    2 / 14 (14.29%)
    1 / 6 (16.67%)
    0 / 84 (0.00%)
    0 / 88 (0.00%)
    0 / 81 (0.00%)
    0 / 25 (0.00%)
         occurrences all number
    2
    1
    0
    0
    0
    0
    Rectal haemorrhage
         subjects affected / exposed
    1 / 14 (7.14%)
    0 / 6 (0.00%)
    0 / 84 (0.00%)
    2 / 88 (2.27%)
    0 / 81 (0.00%)
    0 / 25 (0.00%)
         occurrences all number
    1
    0
    0
    3
    0
    0
    Oral disorder
         subjects affected / exposed
    0 / 14 (0.00%)
    1 / 6 (16.67%)
    0 / 84 (0.00%)
    0 / 88 (0.00%)
    0 / 81 (0.00%)
    0 / 25 (0.00%)
         occurrences all number
    0
    1
    0
    0
    0
    0
    Nausea
         subjects affected / exposed
    6 / 14 (42.86%)
    4 / 6 (66.67%)
    45 / 84 (53.57%)
    31 / 88 (35.23%)
    21 / 81 (25.93%)
    12 / 25 (48.00%)
         occurrences all number
    11
    4
    74
    44
    30
    24
    Eructation
         subjects affected / exposed
    1 / 14 (7.14%)
    0 / 6 (0.00%)
    1 / 84 (1.19%)
    1 / 88 (1.14%)
    0 / 81 (0.00%)
    0 / 25 (0.00%)
         occurrences all number
    1
    0
    1
    1
    0
    0
    Dyspepsia
         subjects affected / exposed
    1 / 14 (7.14%)
    1 / 6 (16.67%)
    9 / 84 (10.71%)
    7 / 88 (7.95%)
    3 / 81 (3.70%)
    3 / 25 (12.00%)
         occurrences all number
    1
    1
    9
    8
    3
    6
    Flatulence
         subjects affected / exposed
    0 / 14 (0.00%)
    0 / 6 (0.00%)
    3 / 84 (3.57%)
    5 / 88 (5.68%)
    0 / 81 (0.00%)
    0 / 25 (0.00%)
         occurrences all number
    0
    0
    3
    5
    0
    0
    Skin and subcutaneous tissue disorders
    Night sweats
         subjects affected / exposed
    1 / 14 (7.14%)
    0 / 6 (0.00%)
    3 / 84 (3.57%)
    0 / 88 (0.00%)
    1 / 81 (1.23%)
    1 / 25 (4.00%)
         occurrences all number
    1
    0
    4
    0
    1
    1
    Onycholysis
         subjects affected / exposed
    0 / 14 (0.00%)
    1 / 6 (16.67%)
    0 / 84 (0.00%)
    1 / 88 (1.14%)
    0 / 81 (0.00%)
    0 / 25 (0.00%)
         occurrences all number
    0
    1
    0
    1
    0
    0
    Hyperhidrosis
         subjects affected / exposed
    1 / 14 (7.14%)
    1 / 6 (16.67%)
    1 / 84 (1.19%)
    0 / 88 (0.00%)
    3 / 81 (3.70%)
    0 / 25 (0.00%)
         occurrences all number
    1
    1
    2
    0
    4
    0
    Haemorrhage subcutaneous
         subjects affected / exposed
    1 / 14 (7.14%)
    0 / 6 (0.00%)
    0 / 84 (0.00%)
    0 / 88 (0.00%)
    0 / 81 (0.00%)
    0 / 25 (0.00%)
         occurrences all number
    1
    0
    0
    0
    0
    0
    Ecchymosis
         subjects affected / exposed
    1 / 14 (7.14%)
    0 / 6 (0.00%)
    0 / 84 (0.00%)
    1 / 88 (1.14%)
    1 / 81 (1.23%)
    0 / 25 (0.00%)
         occurrences all number
    1
    0
    0
    1
    1
    0
    Rash
         subjects affected / exposed
    1 / 14 (7.14%)
    3 / 6 (50.00%)
    10 / 84 (11.90%)
    5 / 88 (5.68%)
    3 / 81 (3.70%)
    2 / 25 (8.00%)
         occurrences all number
    1
    5
    16
    7
    3
    3
    Rash maculo-papular
         subjects affected / exposed
    2 / 14 (14.29%)
    2 / 6 (33.33%)
    4 / 84 (4.76%)
    1 / 88 (1.14%)
    1 / 81 (1.23%)
    7 / 25 (28.00%)
         occurrences all number
    3
    3
    9
    2
    1
    14
    Renal and urinary disorders
    Acute kidney injury
         subjects affected / exposed
    1 / 14 (7.14%)
    1 / 6 (16.67%)
    2 / 84 (2.38%)
    2 / 88 (2.27%)
    0 / 81 (0.00%)
    0 / 25 (0.00%)
         occurrences all number
    1
    1
    4
    2
    0
    0
    Renal pain
         subjects affected / exposed
    0 / 14 (0.00%)
    1 / 6 (16.67%)
    1 / 84 (1.19%)
    0 / 88 (0.00%)
    0 / 81 (0.00%)
    0 / 25 (0.00%)
         occurrences all number
    0
    1
    1
    0
    0
    0
    Urinary incontinence
         subjects affected / exposed
    1 / 14 (7.14%)
    0 / 6 (0.00%)
    3 / 84 (3.57%)
    2 / 88 (2.27%)
    0 / 81 (0.00%)
    0 / 25 (0.00%)
         occurrences all number
    1
    0
    3
    2
    0
    0
    Hypertonic bladder
         subjects affected / exposed
    1 / 14 (7.14%)
    0 / 6 (0.00%)
    0 / 84 (0.00%)
    0 / 88 (0.00%)
    0 / 81 (0.00%)
    0 / 25 (0.00%)
         occurrences all number
    1
    0
    0
    0
    0
    0
    Haematuria
         subjects affected / exposed
    0 / 14 (0.00%)
    0 / 6 (0.00%)
    10 / 84 (11.90%)
    6 / 88 (6.82%)
    5 / 81 (6.17%)
    1 / 25 (4.00%)
         occurrences all number
    0
    0
    16
    13
    6
    1
    Dysuria
         subjects affected / exposed
    1 / 14 (7.14%)
    0 / 6 (0.00%)
    8 / 84 (9.52%)
    2 / 88 (2.27%)
    2 / 81 (2.47%)
    2 / 25 (8.00%)
         occurrences all number
    1
    0
    9
    4
    2
    2
    Pollakiuria
         subjects affected / exposed
    1 / 14 (7.14%)
    1 / 6 (16.67%)
    3 / 84 (3.57%)
    9 / 88 (10.23%)
    0 / 81 (0.00%)
    0 / 25 (0.00%)
         occurrences all number
    1
    1
    3
    11
    0
    0
    Musculoskeletal and connective tissue disorders
    Arthralgia
         subjects affected / exposed
    2 / 14 (14.29%)
    1 / 6 (16.67%)
    17 / 84 (20.24%)
    17 / 88 (19.32%)
    21 / 81 (25.93%)
    3 / 25 (12.00%)
         occurrences all number
    4
    1
    33
    30
    27
    3
    Back pain
         subjects affected / exposed
    1 / 14 (7.14%)
    0 / 6 (0.00%)
    18 / 84 (21.43%)
    20 / 88 (22.73%)
    20 / 81 (24.69%)
    1 / 25 (4.00%)
         occurrences all number
    1
    0
    25
    41
    28
    3
    Bone pain
         subjects affected / exposed
    1 / 14 (7.14%)
    1 / 6 (16.67%)
    12 / 84 (14.29%)
    12 / 88 (13.64%)
    18 / 81 (22.22%)
    1 / 25 (4.00%)
         occurrences all number
    1
    1
    20
    15
    20
    1
    Flank pain
         subjects affected / exposed
    1 / 14 (7.14%)
    0 / 6 (0.00%)
    2 / 84 (2.38%)
    3 / 88 (3.41%)
    0 / 81 (0.00%)
    0 / 25 (0.00%)
         occurrences all number
    2
    0
    2
    3
    0
    0
    Muscle spasms
         subjects affected / exposed
    0 / 14 (0.00%)
    0 / 6 (0.00%)
    3 / 84 (3.57%)
    6 / 88 (6.82%)
    2 / 81 (2.47%)
    0 / 25 (0.00%)
         occurrences all number
    0
    0
    5
    6
    2
    0
    Muscular weakness
         subjects affected / exposed
    1 / 14 (7.14%)
    1 / 6 (16.67%)
    1 / 84 (1.19%)
    7 / 88 (7.95%)
    3 / 81 (3.70%)
    0 / 25 (0.00%)
         occurrences all number
    1
    1
    1
    8
    3
    0
    Musculoskeletal chest pain
         subjects affected / exposed
    1 / 14 (7.14%)
    0 / 6 (0.00%)
    7 / 84 (8.33%)
    5 / 88 (5.68%)
    7 / 81 (8.64%)
    0 / 25 (0.00%)
         occurrences all number
    1
    0
    19
    8
    10
    0
    Myalgia
         subjects affected / exposed
    4 / 14 (28.57%)
    1 / 6 (16.67%)
    6 / 84 (7.14%)
    3 / 88 (3.41%)
    5 / 81 (6.17%)
    0 / 25 (0.00%)
         occurrences all number
    5
    1
    8
    3
    5
    0
    Neck pain
         subjects affected / exposed
    1 / 14 (7.14%)
    0 / 6 (0.00%)
    2 / 84 (2.38%)
    4 / 88 (4.55%)
    3 / 81 (3.70%)
    1 / 25 (4.00%)
         occurrences all number
    2
    0
    2
    4
    3
    1
    Pain in extremity
         subjects affected / exposed
    2 / 14 (14.29%)
    0 / 6 (0.00%)
    13 / 84 (15.48%)
    13 / 88 (14.77%)
    8 / 81 (9.88%)
    4 / 25 (16.00%)
         occurrences all number
    3
    0
    15
    24
    14
    4
    Pain in jaw
         subjects affected / exposed
    1 / 14 (7.14%)
    0 / 6 (0.00%)
    3 / 84 (3.57%)
    1 / 88 (1.14%)
    1 / 81 (1.23%)
    0 / 25 (0.00%)
         occurrences all number
    2
    0
    4
    1
    1
    0
    Infections and infestations
    Fungal urethritis
         subjects affected / exposed
    1 / 14 (7.14%)
    0 / 6 (0.00%)
    0 / 84 (0.00%)
    0 / 88 (0.00%)
    0 / 81 (0.00%)
    0 / 25 (0.00%)
         occurrences all number
    1
    0
    0
    0
    0
    0
    Urinary tract infection
         subjects affected / exposed
    2 / 14 (14.29%)
    0 / 6 (0.00%)
    14 / 84 (16.67%)
    7 / 88 (7.95%)
    6 / 81 (7.41%)
    3 / 25 (12.00%)
         occurrences all number
    3
    0
    16
    12
    9
    3
    Nasopharyngitis
         subjects affected / exposed
    2 / 14 (14.29%)
    0 / 6 (0.00%)
    5 / 84 (5.95%)
    7 / 88 (7.95%)
    3 / 81 (3.70%)
    0 / 25 (0.00%)
         occurrences all number
    2
    0
    6
    9
    3
    0
    Influenza
         subjects affected / exposed
    0 / 14 (0.00%)
    0 / 6 (0.00%)
    5 / 84 (5.95%)
    4 / 88 (4.55%)
    3 / 81 (3.70%)
    0 / 25 (0.00%)
         occurrences all number
    0
    0
    5
    4
    3
    0
    Metabolism and nutrition disorders
    Hypocalcaemia
         subjects affected / exposed
    1 / 14 (7.14%)
    0 / 6 (0.00%)
    6 / 84 (7.14%)
    4 / 88 (4.55%)
    4 / 81 (4.94%)
    1 / 25 (4.00%)
         occurrences all number
    1
    0
    9
    5
    5
    1
    Hypertriglyceridaemia
         subjects affected / exposed
    1 / 14 (7.14%)
    0 / 6 (0.00%)
    1 / 84 (1.19%)
    3 / 88 (3.41%)
    0 / 81 (0.00%)
    0 / 25 (0.00%)
         occurrences all number
    1
    0
    1
    4
    0
    0
    Hyperkalaemia
         subjects affected / exposed
    0 / 14 (0.00%)
    1 / 6 (16.67%)
    1 / 84 (1.19%)
    0 / 88 (0.00%)
    1 / 81 (1.23%)
    0 / 25 (0.00%)
         occurrences all number
    0
    1
    1
    0
    1
    0
    Hyperglycaemia
         subjects affected / exposed
    6 / 14 (42.86%)
    2 / 6 (33.33%)
    19 / 84 (22.62%)
    7 / 88 (7.95%)
    5 / 81 (6.17%)
    8 / 25 (32.00%)
         occurrences all number
    7
    4
    26
    12
    8
    18
    Failure to thrive
         subjects affected / exposed
    0 / 14 (0.00%)
    1 / 6 (16.67%)
    0 / 84 (0.00%)
    0 / 88 (0.00%)
    0 / 81 (0.00%)
    0 / 25 (0.00%)
         occurrences all number
    0
    1
    0
    0
    0
    0
    Hypovolaemia
         subjects affected / exposed
    0 / 14 (0.00%)
    1 / 6 (16.67%)
    0 / 84 (0.00%)
    0 / 88 (0.00%)
    0 / 81 (0.00%)
    0 / 25 (0.00%)
         occurrences all number
    0
    1
    0
    0
    0
    0
    Decreased appetite
         subjects affected / exposed
    5 / 14 (35.71%)
    1 / 6 (16.67%)
    21 / 84 (25.00%)
    21 / 88 (23.86%)
    12 / 81 (14.81%)
    2 / 25 (8.00%)
         occurrences all number
    5
    1
    31
    28
    13
    3
    Hypokalaemia
         subjects affected / exposed
    0 / 14 (0.00%)
    2 / 6 (33.33%)
    8 / 84 (9.52%)
    6 / 88 (6.82%)
    7 / 81 (8.64%)
    4 / 25 (16.00%)
         occurrences all number
    0
    2
    20
    13
    9
    7
    Dehydration
         subjects affected / exposed
    3 / 14 (21.43%)
    2 / 6 (33.33%)
    3 / 84 (3.57%)
    2 / 88 (2.27%)
    2 / 81 (2.47%)
    2 / 25 (8.00%)
         occurrences all number
    3
    2
    3
    2
    2
    2
    Increased appetite
         subjects affected / exposed
    1 / 14 (7.14%)
    0 / 6 (0.00%)
    0 / 84 (0.00%)
    0 / 88 (0.00%)
    0 / 81 (0.00%)
    0 / 25 (0.00%)
         occurrences all number
    1
    0
    0
    0
    0
    0
    Hypomagnesaemia
         subjects affected / exposed
    0 / 14 (0.00%)
    0 / 6 (0.00%)
    6 / 84 (7.14%)
    1 / 88 (1.14%)
    2 / 81 (2.47%)
    0 / 25 (0.00%)
         occurrences all number
    0
    0
    6
    1
    2
    0
    Hypoglycaemia
         subjects affected / exposed
    0 / 14 (0.00%)
    0 / 6 (0.00%)
    0 / 84 (0.00%)
    0 / 88 (0.00%)
    1 / 81 (1.23%)
    2 / 25 (8.00%)
         occurrences all number
    0
    0
    0
    0
    1
    2

    More information

    Close Top of page

    Substantial protocol amendments (globally)

    Were there any global substantial amendments to the protocol? Yes
    Date
    Amendment
    30 Jan 2012
    The following major changes were made in Amendment: 1) For Phase Ib, the exclusion criteria were changed: Participants who had received selected prior anti-cancer therapies (cytochrome P 17 inhibitors including abiraterone, inhibtors of Akt, PI3K/mTOR) were allowed. 2) For Phase Ib and II, participants who had received previous therapies with ketoconazole and/or MDV3100 (i.e., enzalutamide) were allowed to enroll. 3) The definition of DLT with respect to liver parameters was modified. 4) The number of sites participating in this study was increased from approximately 50 to approximately 70 sites. 5) Prednisolone was added as an alternative to prednisone. 6) Denosumab was added to the list of allowed concomitant therapies.
    29 Apr 2012
    The amendment was released to clarify the process for unblinding of treatment assignment by the investigator through the interactive voice response system/interactive web response system.
    11 Sep 2012
    The amendment was released to introduce the following main changes: 1) The study was amended to indicate the recommended dose of ipatasertib (GDC-0068, 400 mg daily) in combination with abiraterone for the Phase II part of the study, on the basis of safety and pharmacokinetic data from the Phase Ib portion. In addition, because of adverse events observed with the combination apitolisib (GDC-0980, 30 mg daily) and abiraterone, further exploration of this combination in the study was discontinued. 2) The design of the Phase II portion of the study was amended accordingly. 3) Updated dose-modification guidelines for the management of hyperglycemia, skin toxicity, gastrointestinal toxicities, and pneumonitis were included.
    06 Mar 2013
    The following major changes were made in Amendment: 1) Eligibility criteria were modified to exclude patients with poor performance status (Eastern Cooperative Oncology Group [ECOG] 2). 2) Accordingly, the stratification factors in the Phase II portion of the study were changed: randomization was stratified by prior enzalutamide (yes vs. no), progression factor (PSA only vs. other), and number of prior chemotherapy regimens for metastatic disease (one vs. more than one). 3) Dose modification for prednisone was added. 4) Risk of abiraterone on the fetus was added. 5) Dose reduction of ipatasertib/placebo or apitolisib was added as an option for management of fasting Grade ≥ 3 hyperglycemia if fasting glucose levels recovered to Grade less than or equal to 2 within 3 days upon dose interruption. 6) Cases of potential drug-induced liver injury that included an elevated alanine aminotransferase or aspartate aminotransferase in combination with either an elevated bilirubin or clinical jaundice, and suspected transmission of an infectious agent by the study drug were added as protocol defined events of special interest.
    27 Nov 2013
    The disease inclusion criterion was updated to align with the study title and rationale that participants who progressed from docetaxel-based chemotherapy (including docetaxel and cabazitaxel, sharing the same cytotoxic mechanism) should be eligible.
    15 Sep 2017
    The amendment was released with the following updates: 1) Facilitate study closure of the Phase Ib portion of the study, while allowing current participants in the Phase II portion of the study to stay on treatment. 2) A section on the Management of Selected Identified and Potential Risks of Ipatasertib was added. 3) Laboratory assessments were streamlined and reduced for ongoing participants. 4) The survival follow-up assessments were removed. 5) The use of the following treatments was removed from the list of prohibited therapies: for apitolisib, proton pump inhibitors (it was recommended that these agents be replaced with an H2-receptor antagonist when feasible), and orally administered H2-receptor antagonists within 10 hours before and 2 hours after apitolisib dose.
    24 Apr 2019
    The amendment was released with the following updates: 1) Include a new safety cohort to the study. The purpose of the safety cohort was to use new technology, a continuous glucose monitoring device, to assess the impact of ipatasertib monotherapy, ipatasertib plus prednisone/prednisolone, and ipatasertib plus prednisone/prednisolone plus abiraterone on glucose levels. 2) Compare morning versus evening dosing of ipatasertib with regard to its impact on glucose levels. 3) Explore the potential drug-drug interaction between abiraterone and ipatasertib and/or its metabolite, G-037720.
    02 Jun 2020
    The amendment was released with the following updates: 1) Harmonize the inclusion criteria of fasting total serum glucose and HbA1c between the Safety cohort and the Phase II portion of the study. 2) Implement additional changes concerning safety reporting and management of risks as well as further definition of the retinal disorder central subfield thickness.
    02 Jun 2021
    The amendment was released to clarify the access to ipatasertib for participants assigned to this treatment after completion of the study.

    Interruptions (globally)

    Were there any global interruptions to the trial? No

    Limitations and caveats

    Limitations of the trial such as small numbers of subjects analysed or technical problems leading to unreliable data.
    None reported
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Fri May 02 08:12:44 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA